Role of transforming growth factor beta in human glioblastoma multiforme cancer stem cells and in tumorigenesis by Kumar, Praveen
 ROLE OF TRANSFORMING GROWTH FACTOR BETA IN HUMAN 
GLIOBLASTOMA MULTIFORME CANCER STEM CELLS AND IN 
TUMORIGENESIS 
 
 
 
 Von der Fakultät für Mathematik, Informatik und Naturwissenschaften  
der RWTH Aachen University 
zur Erlangung des akademischen Grades eines Doktors der  
Naturwissenschaften genehmigte Dissertation  
 
 
 
vorgelegt von  
 
 
 
Praveen Kumar 
aus Jamshedpur, Indien 
 
 
 
  
                         Berichter: PD Dr. Christoph Beier 
 
    Universitätsprofessor Dr. Hermann Wagner  
 
 
 
                                      Tag der mündlichen Prüfung: 20. November 2012  
 
 
 
 
Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfügbar.  
 
 
 
2 
 
 
 
                        
 
 
 
TO MY MOTHER 
 
 
 
 
 
 
 
3 
 
Contents 
1 Contents .................................................................................................................................. 3 
Abbreviations ........................................................................................................................ 6 
List of figures and tables ...................................................................................................... 9 
2 General Introduction .......................................................................................................... 11 
2.1 Brain tumors and their classification  ......................................................................... 11 
2.1.1 Background  ............................................................................................................. 11 
2.1.2 Classification of human brain tumors  ..................................................................... 11 
2.1.3 Frequent aberrations in glioma  ............................................................................... 14 
2.2 Cancer Stem Cells  ........................................................................................................ 17 
2.2.1 CSC theory  .............................................................................................................. 17 
2.2.2 Properties of CSC  ................................................................................................... 19 
2.2.3 Cancer stem cells and normal stem cells ................................................................. 21 
2.2.4 Conventional and recent cell culture systems    ....................................................... 23 
2.2.5 CD133  ..................................................................................................................... 24 
2.2.6 Putative Cells of Origin of GBM  ............................................................................ 25 
2.2.7 Niche and CSC  ........................................................................................................ 26 
2.3 TGF-beta  ...................................................................................................................... 28 
2.3.1 Mechanisms leading to loss of anti-proliferative response to TGF-beta  ................ 33 
2.3.2 CSC and Immune response  ..................................................................................... 34 
2.4 P53  ................................................................................................................................. 35 
2.4.1 P53  .......................................................................................................................... 35 
2.4.2 P53 in stem cells  ..................................................................................................... 36 
2.4.3 Functional loss of p53  ............................................................................................. 37 
2.4.4 Brain tumor models based on loss of p53 and other tumor suppressors. ................. 37 
2.5 NSC  ............................................................................................................................... 38 
3 Scope of Study  ..................................................................................................................... 41 
4 
 
4 Author’s contributions  ....................................................................................................... 42 
5 Materials and Methods  ...................................................................................................... 45 
5.1 Cell culture  ................................................................................................................... 45 
5.1.1 GBM samples and primary GBM CSC culture  ...................................................... 45 
5.1.2 Neural Stem Cell culture  ......................................................................................... 45 
5.1.3 CCL-64 culture for growth inhibition assay for TGF-beta  ..................................... 46 
5.1.4 PBMC isolation and culture  .................................................................................... 46 
5.1.5 Clonogenicity Assay  ............................................................................................... 46 
5.2 Biochemical methods  ................................................................................................... 47 
5.2.1 Quantitative real-time-PCR  .................................................................................... 47 
5.2.2 Reverse Transcriptase PCR ..................................................................................... 47 
5.2.3 SDS-PAGE and Western blot  ................................................................................. 47 
5.2.4 Flow Cytometry  ...................................................................................................... 48 
5.2.5 Immunocytochemistry  ............................................................................................ 48 
5.2.6 Immunohistochemistry  ........................................................................................... 49 
5.2.7 Alamar Blue assay  .................................................................................................. 49 
5.2.8 Animals and Genotyping  ........................................................................................ 50 
5.3 Animal experiments  ..................................................................................................... 50 
5.3.1 Intracranial tumor assays  ........................................................................................ 50 
5.3.2 Cryosectioning and Hematoxylin / Eosin staining  ................................................. 50 
5.4 Bioinformatics and Statistics  ...................................................................................... 51 
5.4.1 Bioinformatics  ........................................................................................................ 51 
5.4.2 Statistics  .................................................................................................................. 52 
6 Signature genes indicating different cells of origin of Glioblastoma cancer stem cells as 
guide for TGF-beta targeting therapies ............................................................................... 53 
6.1 Abstract  ........................................................................................................................ 53 
6.2 Introduction .................................................................................................................. 53 
6.3 Materials and Methods ................................................................................................ 54 
6.4 Results  ........................................................................................................................... 58 
6.5 Discussion  ..................................................................................................................... 71 
7 Impaired TGF-beta signaling– an early step in the genesis of glioblastoma cancer stem 
cells ........................................................................................................................................... 76 
5 
 
7.1 Abstract  ........................................................................................................................ 76 
7.2 Introduction .................................................................................................................. 76 
7.3 Materials and Methods ................................................................................................ 77 
7.4 Results  ........................................................................................................................... 80 
7.5 Discussion  ..................................................................................................................... 87 
8 General Discussion  ............................................................................................................. 91 
9 Summary  ............................................................................................................................. 93 
10 Zusammenfassung  ............................................................................................................ 95 
11 Acknowledgement  ............................................................................................................ 97 
12 References  ......................................................................................................................... 98 
13 Curriculum Vitae  ........................................................................................................... 124 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
ABBREVIATIONS 
 
ABC   ATP-binding cassette  
Akt   Protein kinase B 
aNSC   Adult neural stem cell 
bFGF    Basic fibroblast growth factor 
Bmi-1   B lymphoma Mo-MLV insertion region-1  
BMP-2   Bone morphogenetic protein 2  
BMP-4   Bone morphogenetic protein 4  
bp    Base pair  
BrdU    5-bromo-2-deoxyuridine  
BSA    Bovine serum albumine  
CNS    Central nervous system  
CSC    Cancer stem cell 
DAPI    4’,6-Diamidino-2-phenylindole  
DC    Dendritic cell 
DCX    Doublecortin  
DG    Dentate gyrus 
DGC    Dentate granule cells 
DMEM   Dulbecco’s modified eagle media  
DNA    Deoxyribonucleic acid  
EDTA   Ethylenediaminetetraacetic acid  
EGF    Epidermal growth factor 
ELF    Embryonic liver fodrin 
EMT    Epithelial to mesenchymal transition 
ESC cell   Embryonic stem cell  
FBS/FCS   Fetal bovine serum / Fetal calf serum  
FC   Fold change 
fNSC   Fetal neural stem cell 
FSGB   Fish skin gelatin buffer  
GBM     Glioblastoma multiforme 
GDF    Growth differentiation factors  
GFAP   Glial fibrillary acidic protein  
HRP    Horseradish peroxidase  
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2 General Introduction 
2.1 Brain tumors and their classification 
2.1.1 Background 
Glioblastoma (GBM) is the most common and most lethal human primary 
brain tumor with a median survival of 14.6 months despite multimodal therapy (Stupp 
et al., 2005). There are various lines of new and experimental therapies ranging from 
chemotherapy and radiotherapy to the present dendritic-cell (DC) based immune 
therapies that have been tested without a relevant effect on tumorprogression or 
patient survival. However, there are consistent reports on transient or long term 
responses especially after targeting TGF-beta to foster an antitumor response that raise 
hopes but also questioned how to identify suitable patients that may likely respond to 
this new TGF-beta targeting therapy.  
GBM have historically been viewed as a single pathologic entity but mounting 
evidence suggests that distinct glioblastoma substantially differ at the molecular level 
from one patient to another. The studies in this thesis therefore aim to identify the 
molecular difference between various GBM subtypes that can lead to the selection of 
patients that will likely respond to TGF-beta targeting therapies and to avoid treating 
those in which TGF-beta targeting could be counter-productive. The results of this 
thesis provide a new approach to identify GBM that are likely to respond to TGF-beta 
targeting therapies. The second part of the thesis aimed to identify the underlying 
cause for the different role of TGF-beta by investigating effects of TGF-beta in a 
mouse model of premalignant neural stem cells lacking the tumor-suppressor gene 
p53. 
 
2.1.2 Classification of human brain tumors 
Classification of brain tumors is based on the maximum histological 
resemblance to a particular normal cell type. As per the World Health Organization 
(WHO), grading is done on a scale of I-IV, with grade I being the least and grade IV 
being the most malignant. Malignant gliomas lack borders, have excessive 
uncontrolled proliferation, diffuse infiltration, tendency for necrosis, robust 
angiogenesis, high level of resistance to apoptosis and frequent genomic alterations 
(Furnari et al., 2007). This overview on classification of human brain tumors is mainly 
based on the review of Collins 2004 (Collins, 2004). Gliomas are the most common 
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primary brain tumors in the adult that arise in the brain or spinal cord. Based on the 
cell type and grade they are classified as astrocytomas, oligodendrogliomas, 
oligoastrocytomas and ependymomas.  
 
The astrocytomas can be further classified as: 
a) Pilocytic astrocytoma (Grade I) - Usually they occur in the cerebellum of children 
but can be found anywhere from optic nerve to medulla oblongata. They can maintain 
their benign state for many years. Due to this some of the pilocytic astrocytomas can 
be excised resulting in better prognosis. Neurofibromatosis type 1(NF1) patients show 
increased incidence of these tumors. Allelic losses on both 17p and 17q including 
TP53 and NF1 loci have been shown. Some TP53 but no mutations on the NF1 locus 
have been reported in sporadic tumors. Morphologies range widely from the pilocytic, 
bipolar cellular areas with Rosenthal fibers to less cellular protoplasmic astrocytoma-
like areas with eosinophilic granular bodies and clear cells.  
b) Diffuse asctrocytoma (Grade II) - These are found commonly in males, mostly in 
cerebral hemispheres and have been reported to progress to higher malignancy grade 
tumors. The tumor cells resemble astrocytes with less nuclear atypia in them. They 
have a peak incidence between 25 and 50 years of age. Average survival of patients is 
around seven years. Cells of these tumors resemble astrocytes, show very less nuclear 
atypia and have extensions producing a loosely textured matrix. S-100 and GFAP is 
usually expressed by these cells. More than 60% of these tumors show loss of alleles 
on 17p, including TP53 locus, and the retained TP53 allele has mutations in the 
majority of the cases. Most abnormal finding in such Grade II tumors is the absence of 
functional p53 pathway. Overexpression of PDGFRA gene is observed. In some of the 
astrocytomas there is loss of alleles from 13q and 22q and a significant number 
showing loss of 6q. 
c) Anaplastic asctrocytoma (Grade III) – Histologically and immunocytochemically 
they also resemble astrocytes but have increased cellularity compared to grade II 
astrocytomas. The cells are more pleomorphic and have distinct nuclear atypia with 
more mitosis. The average survival of patients is around 3.5 years. The p53 pathway is 
non-functional and in over 60% of the cases this is due to mutations in TP53 gene. The 
TP53 gene mutation occurs at almost the same frequency as seen in astrocytoma 
malignancy grade II. Losses of alleles on 6q, 13q, 17p and 22q occur at similar or 
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higher frequencies in anaplastic astrocytoma as compared to astrocytoma malignancy 
grade II.   
d) GBM (Grade IV) – They are the most common and the most lethal. They have an 
average survival of approximately 14 months and can develop de novo (primary 
GBM) or from a low grade tumor (secondary GBM). pGBM usually show 
overexpression of EGFR, p16 deletions, phosphatase and tensin homolog (PTEN) 
mutations, loss of heterozygosity (LOH) on 10p and less frequently mouse double 
minute 2 (MDM2) amplification (Karcher et al., 2006). These GBM usually occur in 
elderly patients. sGBM show overexpression of PDGF ligand and also the PDGFR as 
their initial detectable alterations often contain p53 mutations and usually develop in 
younger patients (Hermanson et al., 1996; Watanabe et al., 1996; Kleihues and 
Ohgaki, 1999). The pGBM express higher levels of VEGF-A compared to sGBM. In 
contrast, sGBM expressed higher levels of PDGF-AB compared to pGBM (Karcher et 
al., 2006). Another important difference between pGBM and sGBM is the mutation 
related to the isocitrate dehydrogenase (IDH) genes. IDH enzymes play an important 
role in cell metabolism and are responsible for oxidative decarboxylation of isocitrate 
to α-ketoglutarate (α-KG). IDH1 and IDH2 mutations are more frequent in grade II, 
grade III and sGBM(70-75%) whereas in pGBM it is much less (5%) (Kloosterhof et 
al., 2010). They display nuclear atypia, vascularization, enhanced mitotic activity and 
necrosis (Reifenberger and Collins, 2004). They have a peak incidence between 45 
and 70 years of age. Primary GBM (pGBM) are common but secondary GBM 
(sGBM) are less frequent. Among the astrocytic tumors, GBM show the greatest 
numbers of genetic abnormalities. Most of the GBM have disrupted p53 and Rb1 
pathways and over 90% lose alleles from 10q which includes the tumor suppressor 
gene PTEN. Upto 45% of GBM have mutated PTEN. Genes coding for proteins 
involved in the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway have 
also been shown to be mutated although less frequently. 35% of GBM have 
amplification of the epidermal growth factor receptor (EGFR) gene.  
Oligodendrogliomas have some morphological similarities to oligodendrocytes 
and consist of moderately cellular, monomorphic tumors with round nuclei, very few 
mitoses, absence of necrosis and are classified by WHO as malignancy grade II-IV. 
They may express GFAP but do not express any antigen characteristic of normal 
oliogdendrocytes. 
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  Oligoastrocytomas are often referred to as “mixed gliomas” as they present 
with the appearance of astroctytic and oligodendroglial morphological characteristics. 
Such tumor cells could either be found as diffusely mixed or having distinct areas 
within each tumor. 
Ependymomas resemble the ependymal cells and the most common site for 
their occurance is the fourth ventricle followed by the spinal canal, lateral ventricles, 
and the third ventricle. They are grade I-III gliomas and show immunoreactivity for S-
100 protein, glial fibrillary acidic protein (GFAP), and epithelial membrane antigen 
(EMA). 
 
2.1.3 Frequent aberrations in glioma 
There is a wide range of genetic aberrations found in gliomas. Frequently these 
alterations provide a survival edge to the glioma cells by enabling them to evade 
elimination and continue growth. Two important aberrations observed in glioma are 
related to the TGF-beta signaling and p53 pathways which have been discussed in 
detail in chapters 2.3 and 2.4 respectively. The other major aberrations are mentioned 
as follows: 
 
Receptor mediated pathways-  
Receptor tyrosine kinases (RTK) are a large family of cell surface receptors 
having protein tyrosine kinase activity. A wide range of ligands are capable of 
activating them and influence a plethora of cellular processes which include cell 
metabolism, survival, migration, cell-cycle, proliferation and differentiation. Various 
RTK such as EGFR, PDGFR, VEGFR and c-Met have been implicated in glioma 
malignancy (Abounader, 2009; Li et al., 2009b). 
 
a) Epidermal Growth Factor Receptor (EGFR) - Multiple oncogenic pathways active 
in gliomas employ RTK pathway, the most studied being the EGFR. Its activation is 
observed in 60% of GBM (Smith et al., 2001). It was one of the first cell-surface 
glycoproteins that was identified as an oncogene in its amplified or re-arranged form. 
EGFR amplification usually results either from the increase in its copy number or 
from the constitutive activation of EGFRvIII (40% of GBM), a mutant. Deletion of 
exons 2-7 results in the EGFRvIII variant leading to constitutive receptor activity 
(Kuan et al., 2001). EGFR mutations are usually found in anaplastic astrocytoma and 
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primary GBM compared to oligodendrogliomas (Hoang-Xuan et al., 2001; Fallon et 
al., 2004).  There have been various approaches based on EGFR kinase inhibitors but 
the response has been varying (Griffero et al., 2009). Transduction of mouse Nestin+ 
NSC has been shown to result in glioma-like lesions (Bachoo et al., 2002). Also, 
constitutive EGFR activity in combination with PI3K/Akt activation in murine NSC 
results in transformation (Li et al., 2009b). 
 
b) Platelet-Derived Growth Factor Receptor (PDGFR) - There are four types of PDGF 
ligands (PDGF-A to -D) and two different receptors exists (PDGFR alpha and beta). 
Overexpression of PDGF ligands or their receptor PDGFR alpha is frequent in pGBM 
and sGBM, anaplastic astrocytomas and also in low-grade oligodendrogliomas 
(Hartmann et al., 2004; Furnari et al., 2007; Network, 2008). Increased expression 
correlates with higher tumor grade (Hermanson et al., 1992; Di Rocco et al., 1998). 
Usually PDGF signaling overactivity in gliomas is the result of either the 
amplification of ligands or receptors but not much is known about the mechanisms 
involving the initiation and progression of in vivo gliomagenesis. PDGF signal 
activation can influence cell survival, proliferation, motility and also affect 
neighboring cells. In part, PDGF signaling maintains tumor growth by formation of 
intratumoral blood vessel network and also by recruiting stromal cell components to 
the tumor (Lokker et al., 2002; Dong et al., 2004; Shih et al., 2004; Pietras et al., 
2008). 
A cross-talk of PDGF and other secreted factors like VEGF and FGF2 was also 
observed, resulting in modulation of angiogenic properties. This is evident from the 
high expression levels of both PDGFR alpha and VEGFR2 in several human gliomas 
(Puputti et al., 2006).  
c) Vascular Endothelial Growth Factor Receptor (VEGFR) - VEGF along with its 
receptors is an essentially modulator of angiogenesis and vascular permeability. The 
VEGF family comprises VEGF-A to VEGF- E, PIGF, and snake venom VEGF 
(svVEGF) (Takahashi and Shibuya, 2005). VEGF-A is a key regulator of endothelial 
cell physiology and is recognized as a specific growth factor for endothelial cells 
(Takahashi and Shibuya, 2005). VEGF-A is essential for many angiogenic processes 
both in normal and abnormal states, such as tumor vascularization. Two of the major 
biological activities of VEGF-A are stimulation of vascular endothelial cell 
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proliferation (Dong et al., 2004; Swijnenburg et al., 2008) and enhancement of 
vascular permeability (Senger et al., 1983; Keck et al., 1989). PIGF was originally 
discovered in human placenta (Maglione et al., 1991) but its transcripts have been 
found in heart, thyroid gland, lung and skeletal muscle (Persico et al., 1999). PIGF 
binds to VEGFR-1 but not to VEGFR-2 (Park et al., 1994a; Sawano et al., 1996). Loss 
of PlGF resulted in impaired angiogenesis, plasma extravasation and collateral growth 
during ischemia, inflammation, wound healing and cancer (Palmer et al., 2008). 
VEGF-B is particularly abundant in heart and skeletal muscle (Kjellman et al., 2000). 
Studies involving VEGF-B knockout mice have demonstrated the role of VEGF-B in 
pathological vascular remodelling in inflammatory arthritis (Mould et al., 2003) and  
also in protection of the brain from ischaemic injury (Sun et al., 2004). Both VEGF-C 
and VEGF-D bind and activate VEGFR-2 and VEGFR-3. VEGF-C overexpression in 
the epidermis of mice leads to the development of a hyperplastic lymphatic vessel 
network (Jeltsch et al., 1997). Both VEGF-C and VEGF-D induce the migration and 
mitogenesis of cultured endothelial cells (Lohela et al., 2003). VEGF-E binds and 
activates VEGFR-2 but not VEGFR-1 and VEGFR-3. VEGF family proteins have also 
been identified in snake venom and include svVEGF from Bothrops insularis 
(Junqueira de Azevedo et al., 2001) and TfsvVEGF (Trimeresurus flavoviridis 
svVEGF) (Takahashi et al., 2004) from pit vipers. svVEGF in vipers include 
hypotensive factor (Komori et al., 1999), increasing capillary permeability protein 
(Gasmi et al., 2002) and vammin (Yamazaki et al., 2003). Snakes utilize these venom 
specific VEGF in addition to VEGF-A (Takahashi et al., 2004). 
 
d) c-Met - c-Met along with Hepatocyte Growth Factor also known as Scatter Factor 
(HGF/SF) is one of a key player in brain tumor growth and angiogenesis. 
Deregulations in them, in the form of transcriptional overexpression, gene 
amplification and autocrine loop formation are frequently observed in gliomas. 
Increased levels of c-Met in gliomas result in enhancement of tumorigenicity, tumor 
grade and poor prognosis (Rosen et al., 1996; Koochekpour et al., 1997; Moriyama et 
al., 1998; Abounader and Laterra, 2005; Li et al., 2005). HGF is expressed and 
secreted mainly by tumor cells and may act in an autocrine loop by binding to c-Met 
receptors on tumor cells or they may bind to receptors on vascular endothelial cells.  
Activation of HGF/c-Met signaling results in tumor cell proliferation, migration, 
invasion, inhibition of apoptosis and also resistance to chemotherapy and radiotherapy 
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(Koochekpour et al., 1997; Laterra et al., 1997; Bowers et al., 2000; Brockmann et al., 
2003; Hecht et al., 2004; Abounader and Laterra, 2005; Lal et al., 2005; Li et al., 
2005). 
 
e) PI3K/Akt/mTOR axis- 
The signals induced by RTK are transduced downstream by the pro-survival 
PI3K/Akt pathway. PI3K are lipid kinases which generate second messengers 
phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) when activated by the RTK. PIP3 is 
the link between PI3K and downstream effectors such as Akt which is a serine-
threonine kinase. PIP3 also indirectly activates the protein kinase mammalian target of 
rapamycin (mTOR) having the PI3K homology domain. Together this axis is essential 
for cell growth and survival. It was also found that PI3K was one of the pathways 
upregulated in angiogenic fast-growing tumors (Almog et al., 2009). Tumor 
suppressor PTEN acts on PIP3 and antagonizes PI3K signaling. Human Umbilical 
Cord Blood Stem Cells (hUCBSC) have been shown to inhibit the migration of glioma 
cells by the activation of PTEN which results in the downregulation of PI3K/Akt 
pathway (Dasari et al., 2010). This pathway is crucial for the survival of 
medulloblastoma cancer stem cell residing in the perivascular niche post radiation 
treatment (Hambardzumyan et al., 2008). PTEN mutations are frequent in GBM. 
PTEN is located on chromosome 10q which is deleted in majority of human GBM (Li 
et al., 1997; Teng et al., 1997). 40% of GBM show somatic mutations of PTEN and it 
may play a role in lower-grade astrocytomas to GBM (Rasheed et al., 1997; Wang et 
al., 1997). 
 
2.2 Cancer Stem Cells (CSC) 
2.2.1 CSC theory  
To explain the initiation and development of tumors two alternative models 
have been proposed: the stochastic model and the hierarchical model (Fig. 1). The 
stochastic model posits that the tumors are composed of heterogeneous cells and all 
the cells have the potential to be a tumor-founding cell. In contrast, the hierarchical 
model proposes that malignancies are formed of a hierarchy of cells and are driven by 
rare subpopulation of cells referred to as cancer stem cells or tumor initiating cells. 
Only this subset of cells in the tumor has the potential to form tumors (Vescovi et al., 
2006). These cells were initially identified in the hematological malignancies (Bonnet 
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and Dick, 1997) but a growing body of evidence suggests their presence in various 
other forms of tumors (Reya et al., 2001; Ignatova et al., 2002; Hemmati et al., 2003; 
Singh et al., 2003; Al-Hajj and Clarke, 2004; Singh et al., 2004; Menaa et al., 2009). 
Their similarities to stem cells have led to their nomenclature as cancer stem cells. It 
has to be noted that being referred to as stem cells is because of their multipotency and 
self renewal abilities and does not necessarily indicate their stem cell origin. 
The first attempts to culture neurospheres were from human cortical glial 
tumors (Ignatova et al., 2002). Subsequently self-renewing cells were isolated from 
various types of brain tumors like medulloblastoma (Hemmati et al., 2003), GBM 
(Galli et al., 2004; Singh et al., 2004), and ependymoma (Taylor et al., 2005). In brain 
tumors CSC have been enriched with cell-sorting methods (Singh et al., 2004), and by 
their ability to efflux of the marking dye (Kondo et al., 2004).  
The reason for the failure of current cancer therapies is not usually due to a 
lack of primary response or initial induction of remission but due to relapse or tumor 
recurrence after therapy (including surgery, radiotherapy, and chemotherapy). Major 
reasons for this failure include drug resistance of CSC, inefficiency of the therapy 
and/or genetic instability of the cancer cells (Zhou et al., 2009a). Thus one of the 
major challenges is to devise strategies to prevent tumor relapse by targeting their 
putative source. CSC are thought to play crucial role in these recurrences. A response 
of a patient’s tumor sample is quantified by examining the size of the tumor. However, 
this method does not differentiate between mature cells (i.e. differentiated cells) - that 
to not give rise to tumor recurrence - and tumor-initiating cells (i.e. CSC). If CSC 
survive, the cancer is likely to recur which would require more aggressive therapy 
(Clarke and Becker, 2006). Tumors with higher in vitro self-renewal capacity show 
poor clinical outcome (Pallini et al., 2008). Conversely,targeting these CSC will give 
promising results with reduction in tumor mass and/or incidence of tumor recurrence 
(Piccirillo et al., 2006). 
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Figure 1. Cancer stem cell theory (Reya et al., 2001). Top panel: Conventional 
therapies usually target cells with limited proliferative potential which results in 
shrinkage of tumor. As the putative cancer stem cells escape these therapies, 
ultimately the tumor is re-established. In contrast, therapies targeting the cancer stem 
cells result in loss of tumors ability to regenerate and grow. Bottom panel: Solid 
cancer cells have two general models of heterogeneity. a, Tumor cells are 
heterogeneous and most of the cells have the potential to proliferate consistently and 
form new tumors. b, Only a distinct subset of cells have the potential to proliferate 
extensively and form new tumors. Most of the cells lack this ability.  
 
2.2.2 Properties of CSC 
The most important characteristic of CSC is their abitlity to form tumors in 
nonobese diabetic/severe combined immunodeficiency mice after orthotopic or 
subcutaneous transplantation. This assay is the gold standard to show the infinite 
proliferation capacity. Further CSC divide asymmetrically and show multipotency 
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(ability to differentiate to multiple lineages). For the identification of brain tumor stem 
cells mutiple groups have used the neuroshpere assay as mentioned in the previous 
section. These brain tumor cell form neurospheres in culture which show self-
renewing potential and can also differentiate into one or more neural lineages. These 
cells express nestin and markers associated with neural progenitors such as Sox2, 
Bmi1 (Hemmati et al., 2003), Notch, Emx2, Pax6 (Galli et al., 2004) and Jagged1 
(Ignatova et al., 2002). When induced to differentiate these cells express markers of 
mature neurons, astrocytes and oligodendrocytes. Interestingly, although the CSC 
upon differentiation express markers related to differentiation, they fail to express 
markers for terminal differentiation. For example, they express neuronal markers like 
β-tubulin III, but they often fail to express specific markers associated with terminal 
differentiation like NeuN. However, although the CSC are multipotent, they show 
aberrant differentiation. In contrast to neural stem cells, CSC have a strong bias to 
diffentitate into the cell type that is predominant in the patient’s tumor from which 
these cells were isolated (Dirks, 2008). It was believed that the GBM CSC have 
differentiation potential limited to neural lineages. In contrast to NSC it was 
demonstrated that a subset of GBM CSC have both neuronal as well as mesenchymal 
lineages (Ricci-Vitiani et al., 2008). Also, a subset of primary GBM has been shown 
to express mesenchymal stem-like properties (Tso et al., 2006). 
CSC have been shown to posses multiple lines of defense against all the 
naturally occurring checkpoints inhibiting their survival. Two important properties of 
CSC i.e. their self-renewal and multi-lineage differentiation potential have already 
been discussed. Apart from these CSC employ a plethora of rescue mechanisms that 
not only help them to evade both body’s own response and therapeutic approaches but 
also empower them to multiply in adverse conditions.  Bone morphogenic protein,  
Sonic hedgehog and Notch which are crucial  stem-cell and developmental pathways 
are also responsible for the metastatic potential of the CSC (Bailey et al., 2007). 
Targeting self-renewal of the glioma-initiating cell or inducing their 
differentiation has yielded positive results under experimental conditions. 
Homeodomain transcription factor essential for oligodendroglial differentiation 
NKX2.2 expression nullifies the glioma initiation and progression towards malignancy 
induced by the activation of oncogenic signals in neural progenitor cell NPC. It leads 
to oligodendroglial differentiation of CSC (Muraguchi et al., 2011). Blocking of Notch 
pathway resulted in depletion of CSC in embryonal brain tumors by causing cell cycle 
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exit, apoptosis and differentiation (Fan et al., 2006).  DLL-4 which is a Notch ligand 
was blocked and the effect was enhanced when used with irinotecan, a 
chemotherapeutic agent (Hoey et al., 2009). Krüppel-like family of transcription 
factors (KLFs) KLF9 impacts the CSC by binding to Notch1 promoter and 
suppressing its activity ultimately resulting in differentiation and tumor suppression 
(Ying et al., 2010). 
 
2.2.3 Cancer stem cells and normal stem cells 
As normal stem cells seem to be one of the most likely sources of CSC a better 
understanding of normal stem cells will allow better insights into CSC mechanisms. 
The first evidences for the similarities between the two came from studies involving 
blood cells. After total body radiation (TBR) of mice and injection of blood cells 
through tail veins, it was observed that there were clonally derived colonies of blood 
cells in the spleen of mice (Till and Mc, 1961). When transplanted in secondary 
recipients some of the cells from these colonies showed multilineage potential giving 
rise to colonies having all the types of mature blood cells. Similarly, only a fraction of 
malignant blood cells were able to form colonies in mice spleen (Bruce and Van Der 
Gaag, 1963).  
The adult mammalian brain contains specific areas [the subventricular zone 
(SVZ) and the SGZ (subgranular zone of the hippocampus)] that harbor cells with 
multipotency and throughout life these cells self-renew and also give rise to more 
differentiated progenies for the maintenance of the brain tissue (Alvarez-Buylla and 
Lim, 2004). Multiple factors active in the maintenance of SVZ are found to be crucial 
for glioma development (Barami, 2007). The cytoskeletal proteins nestin and 
doublecortin which are also markers for NSC and progenitors respectively are also 
expressed by human glioma cells. The p53 tumor suppressor gene is expressed in SVZ 
and is frequently mutated or deleted in gliomas. The loss of p53 results in proliferative 
advantage to the slow and fast-proliferating SVZ cells associated with their rapid 
differentiation (Gil-Perotin et al., 2006). Loss of p53 in combination with an additional 
mutagenic stimulus results in transformation of SVZ cells (Zhu et al., 2005; Gil-
Perotin et al., 2006). 
NSC have angiogenic potential and express VEGF and its receptors .They have 
been associated with blood vessels (Shen et al., 2008) and same is true for the GBM 
CSC. VEGF is also crucial for the growth of gliomas. GBM contain CD133+ cancer 
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stem-like cells which in turn contains a subpopulation of CD144+ cells giving rise to 
tumor endothelium probably via CD133+/CD144+ progenitors. This was confirmed 
by the identical genomic profiles of the CD133+ cells, their endothelial progenitors 
and the mature endothelium (Wang et al., 2010). On an average 60.7% of endothelial 
cells in GBM have same genetic alterations as the tumor cells thus indicating that a 
significant proportion of endothelial cells in tumors are of neoplastic origin. This was 
also confirmed in vivo as the orthotopic or subcutaneous injections of CSC gave rise to 
tumors with vessels of human endothelial origin. Reduction and degeneration in tumor 
size was seen when these endothelial cells were targeted (Ricci-Vitiani et al., 2010). 
Multiple signaling pathways like Shh, Wnt and Notch involved with the NSC 
self-renewal are also active in the CSC (Clement et al., 2007; Mu et al., 2010). In a 
study by my working group (Lottaz et al., 2010) GBM CSC were classified into two 
groups based on their transcriptional profiles. The transcription profile of Type I CSC 
was similar to that of their putative founder cells i.e. fetal neural stem cells (fNSC). 
Similarly there was only a minor difference in the transcription profile of Type II 
GBM CSC and their putative founder cells i.e. the aNSC. There was no aberrant 
activation of signaling pathways like Notch, Wnt or Shh. Interestingly, both the CSC 
types in relation to their putative founders showed impaired differentiation and 
increased proliferation capacity (Lottaz et al., 2010). 
Further evidence for their similarity comes from the analysis of Sox4 and 
Sox11. Sox4 and Sox11 are critical for neuronal maturation with expressions restricted 
to post-mitotic differentiating neural cells. Usually their expression overlaps but the 
expression of Sox4 progressively decreases in more differentiated neurons and 
increases on Sox11 expression (Bergsland et al., 2006). Also expression of Sox11 in 
glioma CSC results in its neuronal differentiation. Expression of oncogenic Plagl1 is 
downregulated by Sox11 which results in differentiation (Hide et al., 2009). A recent 
report proposed that Sox4 may be a direct target of TGF-beta and induces Sox2 which 
is critical for self-renewal potential of the CSC (Ikushima et al., 2009). Also, 
embryonic stem (ES) cell marker Nanog is expressed more in differentiation-evading 
CSC compared to the normal human neuronal stem cell-population. Nanog has already 
been reported to be crucial for ES cell self-renewal and thus could be a better marker 
distinguishing CSC from NSC (Field et al., 2010). The in vitro cell culture 
requirements for NSC are same as that for GBM CSC. Both cell types require EGF 
and FGF signaling pathway for the maintenance of stem-cell state. NSC have been 
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found to be PDGF responsive with overexpression resulting in arrested differentiation. 
In a subset of GBM CSC PDGFR amplification have been reported. 
 
2.2.4 Conventional and recent cell culture systems 
The cell culture system for the CSC is based on the in vitro propagation of 
NSC (Figure 2). The conventional cell lines such as U87and A172 are maintained in 
media with fetal calf serum (FCS) but the CSC media lacks FCS but contains EGF and 
FGF. Serum causes irreversible differentiation of NSC (Reynolds and Weiss, 1992) 
and the absence of serum in CSC culture allows preserving the ‘‘stemness’’ of the 
CSC. It has been proposed that bFGF most likely acts on quiescent SVZ astrocytes 
(Zheng et al., 2004) and most probably maintains the neural stem cell pool (Zheng et 
al., 2004) whereas EGF-responsive cells are transit-amplifying C cells and a subset of 
SVZ astrocytes (Doetsch et al., 2002). Although at any particular time in culture most 
of the cells are differentiated, these differentiated cells are able to survive only for a 
limited number of passages whereas the CSC are able to proliferate extensively. This 
culture system preserves the self-renewal and differentiation characteristics of the 
CSC just as it does for the NSC. It was shown that the CSC lines had almost identical 
genetic and molecular profiles from the original tumors from which they were isolated 
even after extended culture periods (Lee et al., 2006; Neve et al., 2006). This was not 
true for the conventional cell lines maintained in FBS. Thus CSC culture system 
proves to be the more reliable system for preserving the characteristics of the original 
tumor samples.   
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Figure 2. Isolation and propagation of brain tumor stem cells (Vescovi et al., 
2006). A defined serum-free medium is used for the isolation and propagation of brain 
tumor stem cells. Tumors are dissociated and plated in media containg the mitogens 
EGF and FGF. Due to the lack of serum and low plating density, most of the cells die, 
and only those survive that are able to divide in response to the stem-cell mitogens. 
Repeated dissociation and resuspension of the cells in fresh medium results in 
establishment of the cell line. Removal of growth factors results in the differentiation 
of precursor cells to neurons, astrocytes and oligodendrocytes, which are the three 
primary cell types found in adult mammalian CNS.   
 
2.2.5 CD133 
CD133 was identified as a  marker that is on a stem cell containing  
subpopulation of some brain tumors (Singh et al., 2004; Dell'Albani, 2008) and it was 
shown that as less as 100 of these CD133+ cells could form tumors when 
intracranially transplanted in NOD/SCID mice. CD133 was first referred to as 
“Prominin” in mouse embryonic neural stem cells and later termed as Prominin-1 
(Weigmann et al., 1997; Fargeas et al., 2003). Earlier it was described as an antigen on 
human fetal and adult hematopoietic stem and progenitor cells (Miraglia et al., 1997). 
Its exact function is not clear. The overall survival (OS) and progression-free survival 
(PFS) of patients with CD133+ /Ki67+ cells were very poor (Pallini et al., 2008). In 
vitro CSC analysis could predict clinical outcome and disease progression (Pallini et 
al., 2008). Grade II, III and IV astrocytomas show distinct CD133+ niches and these 
niches had different subpopulations of tumor cells (Christensen et al., 2008). 
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There are certain GBM which are driven by CD133+ CSC. These CD133+ CSC 
have been found to grow as neurospheres in vitro and they give rise to CD133- cells 
which lacked the capacity to form tumors when transplanted in immunodeficient mice, 
thus showing that these CD133- cells were non-tumorigenic. Beier et. al, provided the 
first evidence that GBM could also be driven by CD133- CSC (Beier et al., 2007). 
These CD133- CSC grew adherently and displayed distinct molecular profiles and 
growth characteristics both in vitro and in vivo. Recently it was reported that there 
could be certain GBM in which both CD133+ and CD133- show stem-cell 
characteristics and can give rise to tumors when transplanted in immunodeificient 
mice (Chen et al., 2010). This heterogeneity is even more pronounced than previously 
thought as the same tumor can have self-renewing cells with different in vitro growth 
profiles having tumorigenic potential (Piccirillo et al., 2009). CD133 was identified as 
a marker for enrichment of CSC in some other forms of tumors also but now even in 
these cases it is shown that cell lacking CD133 expression can also form tumors. 
Interestingly, CD133 is expressed by fetal neural stem cells (fNSC), GBM cells, 
ependymal cells but not by adult neural stem cells (aNSC) of the SVZ (Pfenninger et 
al., 2007; Coskun et al., 2008). 
 
2.2.6 Putative Cells of Origin of GBM 
The cellular origin of CSC is yet unknown and hotly debated. Putative cells of 
origin are astrocytes , unipotent neural progenitors like granule cell neuron precursors 
of the cerebellum, multipotent neural progenitors like NG2 precursors, or the 
multipotent neural stem cells (Stiles and Rowitch, 2008). The machinery controlling 
cell division, DNA damage, and signal transduction pathways are the prime targets for 
mutations. Stem cells live longer than the short-lived committed populations and are 
therefore exposed to more genotoxic stress. This makes them more likely targets for 
initial oncogenic mutations (Reya et al., 2001; Pardal et al., 2003). Also like NSC, 
GBM CSC are capable of giving rise to various cell populations and express markers 
of differentiated and undifferentiated cells of all neural lineages. Interestingly, it was 
also observed that the ease or/and incidence of transformation was inversely 
proportional to the commitment level of the cell to be transformed by the deletion 
or/and overexpression of proliferation genes (Alcantara Llaguno et al., 2009). Thus the 
less differentiated cells (stem cells and progenitors) were more easily transformed 
compared to their more committed counterparts (for example astrocytes). Still the 
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identification of the cell of origin is challenging due to various observations. GBM 
could develop from fusion of mesenchymal stem cells with mature or progenitor cells 
(Bjerkvig et al., 2005). It was also observed that the poorly differentiated or the most 
aggressive cells in a tumor have an embryonic stem cell-like gene signature. This 
made the identification of their cellular origin even more obscure (Ben-Porath et al., 
2008). Interestingly, a new phenomenon termed “Chromothripsis” is discovered by 
which a single catastrophic event could lead to massive genomic rearrangement 
resulting in the shorter time lapse to complete transformation. Most of the cells 
experiencing this would not survive but there could be some cells that may, which 
could ultimately lead to cancer (Stephens et al., 2011). 
Recently it was observed that a cocktail of factors could transform a fully 
committed cell to dedifferentiated state and these cells were referred to as induced 
pluripotent stem (iPS) cell (Takahashi et al., 2007). iPS cells have also been generated 
by using recombinant proteins and these cells are termed as protein-induced 
pluripotent stem cells (piPSC) (Zhou et al., 2009b). Also, this phenomenon is even 
more pronounced in the absence of tumor suppressors (Hong et al., 2009; Kawamura 
et al., 2009; Marion et al., 2009; Utikal et al., 2009). Although there are multiple 
putative cells of origin of GBM still the evidence in support of neural stem cell origin 
of CSC far outweighs the proofs in support of alternative origins. 
 
2.2.7 Niche and CSC 
The specialized microenvironment of a stem cell responsible not just for its 
maintenance but also its timely divisions is termed as the “stem cell niche”, a term 
coined by R. Schofield. The concept of stem cell niche was first proposed in 
vertebrates (Schofield, 1978) but the first to be characterized were the D. melanogaster 
testicular and ovarian niches that controlled the stem-cell self-renewal and 
differentiation (Xie and Spradling, 2000). Drosophila midgut is maintained by 
intestinal stem cells (ISC) and a transient niche is developed by the progenitors that 
regulate the specification of stem cells (Mathur et al., 2010). 
A tight balance has to be maintained by the niche by providing the right degree 
of proliferation-inhibiting and proliferation-promoting signals. CSC are assumed to 
arise when stem cells develop mechanisms to overcome these signals and become self-
sufficient in proliferation either by becoming non-responsive to the anti-growth 
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signals or developing mutations that provide dominant proliferation-promoting signals 
(Li and Neaves, 2006).  
Normal NSC reside in close proximity to vascular niches which are regions 
rich in blood vessels (Shen et al., 2004; Ramirez-Castillejo et al., 2006). These niches 
not only guide the NSC in maintaining a proper balance between self-renewal and 
differentiation but also protect the NSC from apoptotic stimuli. Endothelial cells (EC) 
lining blood vessels are crucial components of NSC niche. EC and are believed to 
secrete factors responsible for the survival of stem cells and also for promoting their 
self-renewal (Yang and Wechsler-Reya, 2007). Similar to the NSC niche the 
microenvironment of CSC have been termed as the ‘‘CSC niche’’. It has been shown 
that the gliomas and various other forms of tumors depend to a great extent on 
angiogenesis for their malignant progression (Barami, 2007; Joyce and Pollard, 2009). 
Another critical aspect in the microenvironment of glioma is hypoxia (regions 
of low oxygen concentration) and is a pointer to unfavorable clinical outcome (Jensen, 
2009). Under hypoxic conditions GBM neurospheres showed and an increment in 
stem cell markers and clonogenicity (Wang et al., 2010). The role of niche has become 
increasingly more important in GBM CSC [(Gilbertson and Rich, 2007; Jandial et al., 
2008); Figure 3]. In light of the recent advances on the identification of CSC and their 
origin, the niche seems to have become one of the most important targets for not just 
the identification of CSC but also for their therapeutic targeting (Borovski et al., ; 
Calabrese et al., 2007). 
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Figure 3. Interaction of CSC with vascular niche (Yang and Wechsler-Reya, 2007). 
(A) CSC are found close to blood vessels, where they receive signals for self-renewal 
and generation of transit-amplifying cells. The tumor grows by continued generation 
of transit-amplifying cells by the CSC. (B) Antiangiogenic therapies targeting blood 
vessels lead to the destruction of vascular niche. Due to this the CSC are unable to 
self-renew and are also not able to generate transit-amplifying cells. Due to the limited 
proliferative capacity of transit-amplifying cells, the tumor gradually stops growing 
and involutes.  
 
2.3 TGF-beta 
The transforming growth factor-beta (TGF-beta) superfamily comprises more 
than 100 different proteins which include activins, inhibins, bone morphogenetic 
proteins (BMP) and the TGF-beta molecules. In mammals, the TGF-beta family 
consists of TGF-beta1, TGF-beta2 and TGF-beta3 isoforms (Massague, 1998; Bottner 
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et al., 2000; Hu and Zuckerman, 2001). The active form of TGF-beta is a homodimer 
each consisting of 12.5 kD size and linked together by disulphide bonds (Bottner et al., 
2000; Dennler et al., 2002). There are multiple steps through which TGF-beta 
molecule passes before achieving its active form. Initially it is synthesized as a 
precursor comprising 3 distinct domains: the signal-peptide, the pro-domain and the 
mature protein. The mature form is of 112 amino acids which is bound to Latency 
associated protein (LAP) which in turn is bound to latent TFG-beta-binding protein 
(LTBP).  Activation process starts when LTBP is cleaved by the serine proteases 
releasing the LAP (Massague, 1998; Annes et al., 2003). 
Initially TGF was thought to be an oncogene and thus named as it was shown 
to transform the rat kidney and fibroblast cell lines (Moses et al., 1981; Roberts et al., 
1981).  Soon it was proved that TGF-beta is involved in a spectrum of biological 
responses and controls proliferation, apoptosis, differentiation, migration, ECM 
formation, and inflammatory response (Verrecchia and Mauviel, 2002). It is also a 
significant player in the developmental process and in tissue repair and homeostasis 
(Border and Noble, 1997; Roberts, 1998; Bottner et al., 2000; Massague et al., 2000; 
Unsicker and Strelau, 2000). 
 
Signal transduction pathways 
TGF- beta is involved in a variety of transduction pathways either through 
signal convergence (Smad-dependent pathways) or divergence (Smad-independent 
pathways). This phenomenon enables TGF-beta to be involved in a plethora of cellular 
responses (Massague et al., 2000; Dennler et al., 2002; Aigner and Bogdahn, 2008). 
 
Smad-dependent pathways: 
TGF-beta may transduce its effect by binding to its receptor which consists of 
3 classes i.e. type I (TGFBR1; 53 kD), type II (TGFBR2; 70-100 kD) or type III 
(TGFBR3; 200-400 kD; Massague 1990). Binding of ligand to TGFBR2 leads to the 
formation of a complex with TGFBRI. The highly conserved GS-domain (sequence 
rich in glycine and serine) of TGFBRI is trans-phosphorylated by the TGFBRII kinase 
which results in the activation of TGFBRI kinase. The activated TGFBRI kinase can 
initiate a varity of downstream effectors, Smads being the most important of them all. 
The Smad proteins contain two domains the MH1 and the MH2 with the MH1 being 
responsible for protein-DNA interation and the MH2 being responsible for protein-
30 
 
protein interaction (Shi et al., 1998). Smad group of protein comprises 3 groups the 
receptor-regulated “R-Smads” (Smad1, Smad2, Smad3, Smad5 and Smad8), complex 
“Co-Smads” (Smad 4), and inhibitory “I-Smads” [Smad 6, Smad 7; (Dennler et al., 
2002)]. Smad1, Smad5 and Smad8 mediate the BMP signal whereas the Smad2 and 
Smad3 mediate the TGF-beta signal. Once activated the “R-Smads” forms a complex 
with the Co-Smad4 and translocated to the nucleus where it mediates the required 
target gene transcription (Dennler et al., 2002). Presence of inhibitory Smad nullifies 
the effect of the “R- and “Co-Smads” [(Imamura et al., 1997; Nakao et al., 1997); 
Figure 4]. 
Further fine tuning of TGF-beta effects could result from by the involvement of 
additional corepressors and coactivators.  Both CBP/P300 and MSG1 coactivators 
could be engaged by Smad4 into the transcription complex for the enhancement of 
Smad response (Shioda et al., 1998; Yahata et al., 2000). Alternatively, the TGF 
response can be reduced by the recruitment of corepressors that interact with either 
Smad2 or Smad3. These corepressors could be SNIP1 (Kim et al., 2000a), 
SIP1(Verschueren et al., 1999), TGIF(Wotton et al., 1999), Evi-1 (Kurokawa et al., 
1998), c-Ski (Akiyoshi et al., 1999; Luo et al., 1999) and SnoN (Stroschein et al., 
1999). These isoforms, receptors and Smads vary depending on the stage of glioma 
(Kjellman et al., 2000). 
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Figure 4. TGF-beta signaling pathway through Smads (Aigner and Bogdahn, 
2008). TGF-beta binds to TGFBR2 and this process activates TGFBR1. Activation of 
TGFBR1 induces the Smad cascade of signal transduction. 
 
Smad-independent pathways:  
1) Mitogen-activated protein kinase (MAPK) pathway- Ras, Raf and ERK1/2 are 
involved with the MAPK pathway. Experiments involving Smad4-deficient cells and 
dominant-negative forms of Smads have proved the presence of Smad-independent 
mechanisms of activation of MAPK signaling by TGF-beta (Engel et al., 1999). 
Additionally, TGFBR1 mutants lacking Smad activation are capable of activating 
MAPK signaling in response to TGF-beta (Fuller et al., 2002).  Recently even p53 has 
been identified as the mediator of TGF-beta signal through Ras/MAPK pathways 
(Cordenonsi et al., 2007). 
 
2) c-Jun N-terminal kinase (JNK) pathway- TGF-beta has been shown to activate JNK 
independent of Smad (Engel et al., 1999; Yamaguchi et al., 1999). Furthermore, TGF-
beta and BMP activation of JNK and p38 MAPK is mediated by TGF-beta-activated 
kinase-1 and MAPK kinases (Yamaguchi et al., 1999). 
3) Rho/Rho-associated protein kinase (ROCK) pathway- RhoA and p160ROCK-
dependent signaling mediates the TGF-beta1-induced epithelial to mesenchymal trans-
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differentiation and inhibition (Bhowmick et al., 2001; Bhowmick et al., 2003). Also, 
RhoB is stabilized by TGF-beta, which in turn downregulates TGF-beta signaling 
(Engel et al., 1998). 
  
4) PI3K-Akt pathway- PI3K-Akt pathway is activated by TGF-beta in various cell 
types. Smad independent mechanism is also indicated by the direct interaction of 
TGF-beta receptors with p85 which is the regulatory subunit of PI3K (Yi et al., 2005). 
 
5) Protein phosphatase 2A /S6 kinase pathway- TGF-beta can also signal independent 
of Smads by binding to its receptor and inducing the association of its receptor to 
protein phosphatase 2A. This results in S6-kinase inhibition leading to the G1 arrest of 
the cell cycle (Petritsch et al., 2000). 
 
In various malignant conditions like the malignant gliomas (Jachimczak et al., 
1996; Kjellman et al., 2000), pancreatic carcinomas (Friess et al., 1993)  and 
colorectal carcinomas (Friedman et al., 1995), TGF-beta secretion is enhanced. Due to 
this, TGF-beta signaling has become an important therapeutic target. The two most 
important intracellular signaling pathway involved in the pathobiological effects of 
TGF-beta are the traditional Smad pathway and the MAPK pathway (Nickl-Jockschat 
et al., 2007). TGF-beta signaling through the Smad pathway has been characterized to 
be mainly anti-proliferative (Massague, 1998), although there have been numerous 
other intracellular signaling cascades identified as TGF-beta signal transductors. The 
MAPK pathway which results in induction of a mesenchymal phenotype is probably 
the most important of these pathways (Derynck and Zhang, 2003). Loss of anti-
proliferative control and induction of dedifferentiation due to a change in balance 
between Smad and MAPK pathways results in the tumor promoting effects of TGF-
beta on malignant cell types (Akhurst and Derynck, 2001) but this effect was not well-
studied in high-grade gliomas. Later it was shown that this imbalance between Smad 
and MAPK pathways was responsible for the tumor promoting effects of TGF-beta in 
high grade gliomas (Nickl-Jockschat et al., 2007). A better understanding of this 
imbalance would result in better insights into the role reversal of TGF-beta. This 
overview was based on the review of Aigner and Bogdahn 2006 (Aigner and 
Bogdahn, 2008). 
 
33 
 
2.3.1 Mechanisms leading to loss of anti-proliferative response to TGF-beta 
a) Disruption of TGF-beta pathway - One reason could be the inactivation of 
TGFBR2 due to non-functional TGFBR2 resulting from mutations in 
microsatellites and its corresponding instability. Inactivation either due to 
deletions or due to non-sense, missense or frameshift mutations in Smad2 and 
Smad4 has also been frequently implicated in pathway disruption. Although 
mutations in Smad 3 has not been reported till date in human cancers, lack of 
Smad 3 could also be the reason for pathway disruptions as seen in acute myeloid 
leukemia (Massague, 1998; Siegel and Massague, 2003; Wolfraim et al., 2004). 
Smad 4 has been found to be either deleted or mutated in 50% of pancreatic and 
10% of colon cancers (Massague, 1998; Siegel and Massague, 2003). 
 
b) Loss of anti-proliferative control with an intact TGF-beta pathway- There are 
multiple ways in which this can take place some of which are mentioned below: 
-TGF-beta exercises the anti-proliferative control through the induction of 
p15Ink4b and p21Cip1. Higher levels of Myc repress this induction and thus 
induce the absence of anti-proliferative control (Warner et al., 1999; Claassen and 
Hann, 2000). 
-Transcription factor FoxO plays an important role in the induction of p21Cip1 by 
TGF-beta by forming a complex with Smad. In turn, FoxO is regulated by the 
PI3K-Akt pathway (Brunet et al., 1999; Seoane et al., 2004). After transformation, 
the tumor cells utilize the Akt pathway to exclude FoxO from the cells and thus 
Smad-FoxO complex cannot be formed in these cells which ultimately results in 
the absence of TGF-beta control (Seoane et al., 2004).  
-Akt can also directly prevent the phoshphorylation of Smad3 and thus its 
subsequent nuclear translocation, preventing the TGF-beta mediated apoptosis 
(Conery et al., 2004; Remy et al., 2004). 
-A hyperactive Ras/MAPK pathway may result in the phosphorylation of the 
linker region of Smad2 preventing its nuclear localization (Kretzschmar et al., 
1999; Massague, 2003). This could also be one of the mechanisms for loss of 
TGF-beta control. This overview was based on the review of Seoane 2006 
(Seoane, 2006). 
TGF-beta1 has been shown to be critical for the survival of central nervous 
sytem (CNS) neurons and also for the modulation of microglia activation (Brionne 
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et al., 2003). In a breast cancer model, TGF-beta signaling has been shown to be 
crucial for the survival of cancer cells. Loss of TGF-beta signaling resulted in 
decreased latency period and increased metastasis (Bierie et al., 2008). In a subset 
of gliomas, the role of TGF-beta depends on the methylation status of PDGFR 
gene. In case of an unmethylated PDGRF, TGF-beta acts as an oncogene and 
induces proliferation (Bruna et al., 2007). Only recently, there is emerging 
evidence of the involvement of TGF-beta in CSC (Ikushima et al., 2009; Penuelas 
et al., 2009; Watabe and Miyazono, 2009). 
 
2.3.2 CSC and immune response 
Immune therapy utilizes the body’s own immune response against the tumor 
thus having the possibility to overcome the limitations of conventional therapies (Xu 
et al., 2009). It was earlier shown that soluble factors from human glioma induced 
immunosuppression, and this was by the alteration of cytokine profile and surface 
markers (Zou et al., 1999). Macrophages have been reported to mediate anti-tumor 
response by activating various mechanisms. It has been demonstrated that the tumor 
cells circumvent this check by producing various molecules such as IL-4, IL-6, TGF-
beta1, PGE2, M-CSF and MDF which deactivate the cytoxic activity of activated 
macrophages (Elgert et al., 1998). EGFRvIII is one of the most common mutations of 
EGFR usually amplified in tumors. Vaccination against EGFRvIII was effective in 
both subcutaneous and intra cerebral tumors (Heimberger et al., 2003). CSC express 
large amounts of tumor associated antigens. CSC could be used as a source of antigens 
for dendritic cell (DC) vaccination against these tumors (Xu et al., 2009). There was 
enhanced production of cytotoxic T lymphocytes (CTLs) against the tumor induced by 
this vaccination (Xu et al., 2009). Elimination of CSC by their differentiation through 
STAT3 blockage has therapeutic potential (Wei et al., 2010). Also, CD133+ GBM 
CSC employ the STAT3 pathway to induce immunosuppression, apoptosis and down-
regulation of regulatory T cells. Blockage of the STAT3 pathway resulted in the 
reversal of these conditions (Wei et al., 2010). Expression of STAT3 by cancer cells 
down-regulates MHC class I chain related protein A (MICA) expression on natural 
killer (NK) cells which recognize the tumor cells. Inhibition of STAT3 resulted in the 
release of interferon-gamma by NK cells (Bedel et al., 2011). Although CSC are 
resistant to freshly isolated NK cells, they are prone to lysis by activated allogenic or 
autologous NK cells (Castriconi et al., 2009). GBM CSC are less immunogenic but 
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had high activity against T-cell lymphocytes (Di Tomaso et al., 2010). 
Microphage/microglia constitutes the major components of tumor infiltrating cells. 
The glioma CSC have been shown to suppress adaptive immunity. They also modulate 
innate immunity by producing cytokines like MIC-1, sCSF-1, and TGF-beta1. These 
cytokines recruit microglia and induce them to be immnosuppressive (Wu et al., 
2010). The mesenchymal subtype as identified by Phillips and coworkers (Phillips et 
al., 2006) comprises tumors that  is more refractory to conventional therapies was 
found to be more responsive to autologous tumor lysate-pulsed DC based therapy with 
toll-like receptor TLR agonists (Prins et al., 2010). Interestingly, T-cells post DC-
vaccination have been shown to enhance the ‘‘stemness’’ although the malignancy 
was conditional and dependent on specific host (Irvin et al., 2010). 
 
2.4 P53 
2.4.1 P53 
P53 coordinates a wide range of cellular responses and in turn gets regulated 
by multiple processes. P53 with its ability to induce cell cycle arrest or apoptosis is a 
major threat to potential cancer cells. It is thus imperative for any cancer cell 
advancing towards malignancy to first either mitigate or completely abolish the p53 
activity. MDM2 is a major negative regulator of p53 levels as it ubiquinates p53 and 
results in its proteasomal degradation (Michael and Oren, 2003; Brooks and Gu, 
2006). 
Some of the nicknames used for p53 are the “Guardian of the Genome,” and 
“Guardian of Babies,” for its role in maintaining genomic stability and avoiding 
developmental malformations respectively (Lane, 1992; Hall and Lane, 1997). Under 
normal conditions p53 is unstable and remains in inactive state. This changes under 
genotoxic and oncogenic stresses when it is stabilized and becomes active leading to 
cell cycle arrest, apoptosis or senescence. 
It is one of the most studied proteins with extreme pathologies depending on 
the type of tissue. In the hair follicles and hematopoietic system which are prone to 
p53-dependent apoptosis its activation results in loss of cells. In contrast there are pro-
survival signals in systems like the endothelium of small intestine which show cell-
cycle arrest on p53-activation (Gudkov and Komarova, 2010). During neurogenesis 
excess neuronal progenitors are formed, most of which are eliminated leaving behind 
few that differentiate to form neurons. P53 loss in SVZ cells leads to enhanced 
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proliferation and at the same time an increased p53 expression leads to early loss of 
neurogenic capacity (Medrano and Scrable, 2005). P53 mediates neuronal 
differentiation by modulating dual oxidase maturation factor 1. Dual oxidase 
maturation factor 1 is highly expressed in NSC but declines post-differentiation 
(Ostrakhovitch and Semenikhin, 2011). 
Mutation or deletion of p53 tumor suppressor gene is very common in human 
tumors and its loss is one of the early stages in the genesis of glioma (Louis, 1994). 
Even in human cancers where it is present in the wild-type form, it is rendered non-
functional by disruption of pathways that leads to its activation (Stiewe, 2007; Kruse 
and Gu, 2009) . Thus it plays a major role in preventing neoplastic transformations 
and its loss of function is essential for the genesis of tumors. P53 null mouse models 
have also been generated for various cancer models including breast and brain 
(Blackburn and Jerry, 2002; Zhang et al., 2008). Loss of p53 pathway components is 
responsible for impaired DNA-damage response leading to radiation resistance of 
gliomas (Squatrito et al., 2010). 
 
2.4.2 P53 in stem cells 
P53 controls the delicate balance between aging and cancer. Each damaged cell 
including the stem cells has two choices, either to repair and continue living or die. 
Too much repair could lead to aging and too little could lead to cancer (Schlereth et 
al., 2010). Normal stem cells divide asymmetrically and thus give rise to a stem cell 
with self-renewal abilities and a progenitor cell with a more committed fate. P53 has 
been shown to regulate the polarity of cell division in mammary stem cell and results 
in asymmetric division whereas loss of p53 results in symmetric divisions of CSC 
resulting in tumor growth (Cicalese et al., 2009). It has recently been shown that 
competition in hematopoietic stem and progenitor cells depends on the relative level 
of p53. This could possibly lead to clonal expansion of incipient cancer cells (Bondar 
and Medzhitov, 2010). Loss of MDM2 check on p53 results in p53 mediated 
senescence in the epidermal stem cell compartment and a decrease in stem cell 
numbers and function (Gannon et al., 2011). 
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2.4.3 Functional loss of p53 
 
Mutant p53   
Loss of p53 does not significantly alter the proliferation of adult brain cells. 
Accumulation of mutant p53 first occurs in NSC of SVZ. Genesis of glioma is the 
result of the subsequent expansion of mutant p53 expressing transit-amplifying 
progenitor-like cells in the SVZ (Li et al., 2009c). It was also reported that the 
expression of mutant p53 results in loss of response to TGF-beta. Mutant p53 down-
regulates the expression of TGFBR2 resulting in attenuation of TGF-beta1 signaling 
by SMADs (Kalo et al., 2007). 
Deletion of p53 
Specific genetic abnormalities like loss of p53 cooperates with additional DNA 
damaging agents (like ENU) to give rise to glial neoplasms in adult brain (Leonard et 
al., 2001). Also, p53 in combination with Ink4a/Arf loss results in cancer progression 
and metastasis (Morton et al., 2008). There had been suggested roles of p53 in 
regulation of stem cell compartment (Cordenonsi et al., 2003) and this was validated 
in a breast cancer model. A specific population of tumor-initiating cells was identified 
in p53-null mouse model of breast cancer (Zhang et al., 2008). 
 
2.4.4 Brain tumor models based on loss of p53 and other tumor suppressors.  
Absence of p53 itself is not sufficient for transformation but does result in 
enhanced proliferation of SVZ cells (Gil-Perotin et al., 2006). SVZ cells lacking p53 
do not show unlimited proliferation which is indicative of p53 independent apoptosis 
in these SVZ cells. Transformation of these cells required an additional stimulus along 
with the absence of p53.  
Loss of Ink4a-Arf with EGFR activation leads to glioma formation from both 
NSC and the differentiated astrocytes (Bachoo et al., 2002). Activation of KRas and 
Akt in neural progenitors could lead to GBM formation but this did not have any 
effect on the differentiated astrocytes. It was also shown that KRas and Akt activation 
in astrocytes cooperates with Ink4a-Arf loss to form GBM. In case of neural 
progenitors it leads to increased incidence of GBM formation (Uhrbom et al., 2002). It 
is highly probable that the loss of tumor suppressors leads to dedifferentiation of 
astrocytes and make them prone to transformation. An additional stimulus in the form 
of Ras and Akt activation leads to their transformation. Inactivation of p53 cooperates 
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with NF1 loss leading to formation of malignant astrocytomas with characteristics of 
GBM (Zhu et al., 2005).  PTEN is another important player which influences 
multitude of cellular responses by modulating PI3K signaling (Endersby and Baker, 
2008). In 60-70 % gliomas PTEN is lost and is responsible for the associated 
malignant phenotypes. PTEN had been shown to modulate the PI3K pathway but it 
may also act through the SFK pathway (Dey et al., 2008). Loss of PTEN in adult NSC 
results in enhanced proliferation but without transformation. Also, aNSC lacking 
PTEN are capable of migrating to olfactory bulb (OB) and also differentiate and 
integrate in the circuitry there (Gregorian et al., 2009). P53 and PTEN are active in 
both neural and glioma stem/progenitor cells and responsible for their self-renewal and 
differentiation potential (Zheng et al., 2008a). Neither p53 nor PTEN loss singularly 
results in transformation. Combined loss of both of these tumor-suppressors result in 
c-myc activation in NSC and its subsequent transformation, giving rise to GBM. c-
myc activation is responsible for the enhanced self-renewal and tumorigenic features 
of the transformed NSC (Zheng et al., 2008a). PTEN inactivation accelerates the 
formation of high-grade astrocytomas resulting from NF1/p53 loss (Kwon et al., 
2008). Activation of Ras in p53null astrocytes resulted in cells similar to brain tumor 
stem cells with self-renewal and other related properties (Lee et al., 2008). Activation 
of p53 in animal models of tumors has already shown promising results (Xue et al., 
2007). Also, it has been suggested that small molecules can be used against mutant 
p53 proteins to regain wild-type functions (Joerger et al., 2006). Small molecule 
inhibitors like the Nutlins targeting the p53-Mdm2 interaction have even been used 
successfully against human xenograft models (Vassilev, 2007). 
 
2.5 NSC 
Neural stem cells (NSC) are the self renewing cells in the adult nervous system 
that have the ability to give rise to the entire cell types of the neural lineage namely 
neurons, astrocytes and oligodendrocytes The NSC thus have the ability to replace or 
repair damaged tissue. Contrary to long held view it was shown that there is 
continuous neurogenesis throughout life. In adult mammals this occurs in two specific 
areas of the brain the subventricular zone (SVZ) of the lateral ventricles and the 
subgranular zone (SGZ) of the dentate gyrus (DG). There are three types of cells in the 
SVZ: type B NSC, type C transit amplifying cells, and type A migrating neuroblasts. 
The type B NSC are the slow-dividing cells which give rise to fast proliferating type C 
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transit-amplifying cells. These type C cells in turn give rise to type A neuroblasts 
which migrate through the rostral migratory stream (RMS) to finally reach the 
olfactory bulb (OB) and differentiate to interneurons. The SGZ comprise of type 1 and 
type 2 cells. The type 1 cells are the quiescent NSC and may generate actively 
dividing progenitors (type 2 cells). The type 2 cells in turn give rise to neuroblasts 
which differentiate into local glutamatergic dentate granule cells (DGC) (Mu et al., 
2010). It has also been reported that some of the type 2 cells have the potential to self-
renew and generate both neurons and astrocytes pointing to the reciprocal relationship 
between type 1 and type 2 cells (Suh et al., 2007). 
     
Figure 5. Neurogenesis in the adult brain. (a) The two germinal zones of the brain 
where adult NSCs are primarily located: the SVZ of the lateral ventricles and the SGZ 
of the hippocampal DG. (b) A subpopulation of the quiescent type B cells in the SVZ 
has the potential to serve as adult NSC and generate rapidly dividing, transit-
amplifying nonradial NSC (type C cells). Type C cells give rise to neuroblasts (type A 
cells) that migrate through the RMS toward the OB. (c) In the adult SGZ the quiescent 
radial NSC (type 1 cells) coexist with the actively proliferating nonradial NSC (type 2 
cells). The type 2 cells generate both astrocytes and neuroblasts. These nuuroblasts 
then migrate to the granule cell layer to mature into neurons. (Mu et al., 2010). 
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The NSC can be cultured in serum-free medium containing EGF and bFGF, as 
free-floating neurospheres and also as adherent monolayer cultures (Reynolds and 
Weiss, 1992; Sun et al., 2008). NSC cultures contain heterogeneous populations 
comprising the NSC and also the more committed cells. NSC have been identified in 
humans and also in various other species (Doetsch et al., 1999; Kukekov et al., 1999). 
They have also been directly isolated from human fetal brain tissue using the cell-
surface marker CD133 (Uchida et al., 2000). 
Stem cell self renewal is a complex process as it employs a dynamic interplay 
between cell extrinsic factors including the niche and the transcription factors, miRNA 
regulators and epigenetic controls (Shi et al., 2008). The enzyme telomerase is 
necessary to prevent shortening of the DNA with every division and usually it is 
detected in various types of stem cells. In mice, telomerase expression is seen in all 
regions of the brain shortly after birth. But in adult mice brain this expression is 
restricted only to the SVZ and the OB. Cultures of NSC have been shown to possess 
this activity (Caporaso et al., 2003). 
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3 Scope of Study 
Although TGF-beta is a major regulator of glioma cell proliferation and 
glioma-mediated tumor suppression, nothing was known about the function and 
relevance of TGF-beta on GBM CSC at the beginning of this thesis. As discussed 
above, TGF-beta substantially contributes to the genesis and maintenance of solid 
tumors, the studies of my thesis  
(I) aimed at the characterization of the effects of TGF-beta in a large panel of 
different CSC in vitro and in vivo.  
(II) aimed at an understanding of the differential response of the CSC lines to 
TGF-beta and how the TGF-beta response correlates to the CSC subtype and the 
properties of the original tumor in vivo.  
 (III) aimed at the identification of putative biomarkers that may help to guide 
targeted therapies against TGF-beta that are currently in early and advanced clinical 
studies.  
 (IV) aimed at the investigation of the TGF-beta signaling pathway in a in vitro 
model of early premalignant glioblastoma cells to investigate if disturbances of the 
TGF-beta signaling may constitute an early event in the genesis of GBM. 
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5 Materials and methods 
5.1 Cell culture 
5.1.1 GBM samples and primary GBM CSC culture 
Native tumor tissue samples from GBM resections were provided by the local 
department of Neurosurgery. All tumors were histologically classified according to the 
World Health Organization (WHO) classification of central nervous system tumors 
(Furnari et al., 2007). Experiments were approved by the local ethics committee 
(University of Regensburg, No. 05/105, June 14, 2005). 
Samples were stored in sterile saline at 4°C and processed within 24 h after 
resection. They were washed and dissociated mechanically and enzymatically. 
Erythrocytes were lysed using NH4Cl. Trypan-blue staining confirmed >80% viability 
after the procedure. Tumor cells were then grown in stem cell-permissive DMEM-F12 
medium supplemented with 20 ng/ml of each human recombinant epidermal growth 
factor (EGF), human recombinant basic fibroblast growth factor (bFGF) (both from 
R&D Systems, Wiesbaden, Germany), human leukemia inhibitory factor (LIF) 
(Chemicon, Hampshire, UK), and 2% B27 (Gibco, Karlsruhe, Germany) retaining the 
molecular characteristics of the primary tumor with only minor changes in 
differentiation, expression pattern, and genetic mutation profile (Lee et al., 2006).  
 
5.1.2 Neural Stem Cell culture 
Two to four month-old mice (Charles River Deutschland GmbH, Germany) 
were decapitated and SVZ were dissected. The tissue was homogenized and cells were 
resuspended in Neurobasal (NB) medium (Gibco BRL, Germany) containing B27 
supplement (Gibco BRL, Germany), 2 mM L-glutamine (PAN, Germany), 100 U/ml 
penicillin / 100µg/ml streptomycin (PAN, Germany). For expansion, the NB/B27 was 
growth factor-supplemented with 2 mg/ml heparin (Sigma, Germany), 20 ng/ml FGF-
2 (R&D Systems, Germany) and 20 ng/ml EGF (R&D Systems, Germany) 
(proliferation medium). The cell suspension from SVZ of 2 mice was seeded into a 
T25 flask (TPP, Switzerland) in 5 mL proliferation medium. The cultures were 
maintained at 37 °C in a humidified incubator with 5% CO2 and half of the media was 
changed every 3 to 4 days. For passaging, cells were dissociated by using accutase 
(PAA, Austria) and a total of 5 x 105 cells were seeded in a T75 flask (TPP, 
Switzerland). 
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5.1.3 CCL-64 culture for growth inhibition assay for TGF-beta 
CCL 64 is a mink lung epithelial cell line which shows growth inhibition in the 
presence of active TGF-beta. Briefly, 5 X 103 CCL 64 cells were added to 96-well 
tissue culture plates in a total volume of 50 µl RPMI 1640 supplemented with 2 mM 
glutamine, 10% FCS,  15 mM HEPES and penicillin-streptomycin (P-S; 50 IU-50 
pg/ml). The next day 50 µl and 100 µl triplicate samples of supernatants were added to 
wells. Cultures were incubated for an additional 3 days and at the end of the 
incubation period, the total number of viable cells/well was enumerated. The levels of 
TGF-beta were determined with a standard curve of viable CCL 64 cells, as a function 
of known TGF-beta concentrations (0.1-10 ng/ml). In parallel, experiments were 
performed with supernatants in the presence of neutralizing polyclonal anti-TGF-beta 
antibodies that exhibits high specificity for human TGF-beta. Proper vehicle controls 
were performed because TGF-beta standards were dissolved in 0.02% BSA. At the 
end of the assay period, the vehicle and media controls resulted in comparable cell 
numbers. 
 
5.1.4 PBMC isolation and culture 
Peripheral blood mononuclear cells (PBMC) were separated by Ficoll-Paque 
(GE Healthcare) density gradient centrifugation from blood obtained from healthy 
volunteers. 15 ml of Ficoll was taken in a 50 ml falcon and 35 ml of blood/PBS 
mixture (1:1 ratio) was poured over the mixture. This was centrifuged at 600 rotations 
per minute (rpm) at 20°C for 20 min without brakes and the serum was discarded. 
Once more it was centrifuged at 1400 rpm at 20°C for 20 min without brakes. The 
cells seen at the interface was carefully extracted. Cells were PBS washed and finally 
resuspended in RPMI 1640 (PAA, Austria) supplemented with 10% FBS, 2 mM l-
glutamine, and 1% penicillin/ streptomycin. Freshly isolated PBMC were incubated at 
37°C in complete medium and allowed to adhere for 1h in a 48 well plate at 37°C in a 
humidified atmosphere of 95% air/5% CO2. The adherent cells comprising the 
monocyte population were removed and the non-adherent cells were collected for 
further study. 
 
5.1.5 Clonogenicity Assay 
 Clonogenicity assay was performed in 96 well plates and cells were incubated 
with various concentrations of TGF-beta1, TGF-beta2, or both. The medium 
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supplemented with TGF-beta was replaced depending on the growth rate of cell lines. 
For every condition there were 10 wells with 50 cells in each well. The number of 
spheres/patches was determined at the end of 1-4 weeks. 
 
5.2 Biochemical methods 
 
5.2.1 Quantitative real-time-PCR 
RNA was extracted with the RNeasy kit (QIAGEN GmbH, Hilden, Germany) 
and cDNA was synthesized using the Reverse Transcription System (Promega GmbH, 
Mannheim, Germany). Real-Time-PCR was performed with the QuantiTect SYBR 
Green PCR kit (QIAGEN) using the Stratagene Mx3000P Real-Time PCR system 
(Stratagene Europe). PCR reactions were run as triplicates on 96-well plates. 
Temperature profile: 95°C (15 min) followed by 45 cycles: 95°C (20 s) - 58°C (30 s). 
The quality of the products was controlled by a melting curve. For quantification, 
standard curves were established by amplification of serial dilutions of cDNA for both 
the target gene and the endogenous reference (18S RNA).  
 
5.2.2 Reverse Transcriptase PCR 
RNeasy Kit (Qiagen, Germany) was used to extract total RNA from the cells 
following the manufacturer’s instructions. Using a standard spectrophotometer, optical 
density measurements at wavelengths of 260 and 280 nm was done to measure the 
purity of isolated RNA. 1µg of total RNA was used to synthesize single stranded c-
DNAs using the reverse transcription kit (Promega, Germany). PCRs were performed 
for 30 cycles (30 seconds at 94 °C, 2 min at 66 °C and 1 min at 72 °C ) using primers 
for Smad2, Smad7 and the house-keeping gene beta-actin. PCR products were 
visualized under UV-illuminator after 1% agarose gel electrophoresis and ethidium 
bromide staining. 
 
5.2.3 SDS-PAGE and Western blot 
 Immunoblotting was done by homogenizing cells on ice in 
radioimmunoprecipitation assay (RIPA) buffer containing of 50 mM Tris-HCl (pH 
7.4) hypotonic buffer with 1 mM EDTA, 1% Nonidet P-40 (Sigma, Igepal, CA), and 
protease inhibitor cocktail (Complete Mini, Protease inhibitor cocktail tablets, Roche, 
Mannheim, Germany). This was followed by centrifugation for 15 min at 15,000 rpm 
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and 4°C. The protein concentration was determined using BCA test (Sigma, 
Taufkirchen, Germany) the resulting supernatants (30-50 ug of total protein) were 
size-separated by 10-15% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membrane 
(Schleicher and Schuell, Dassel, Germany) by semidry electroblot method (Biometra 
Fast blot, Biometra Biomedizinische Analytik, Göttingen, Germany). Protein transfer 
of the samples to the nitrocellulose membrane was confirmed with Ponceau-S staining 
of the membranes. The unspecific binding sites were blocked with 5 % non-fat milk in 
TBST buffer (20 mM Tris, 0.15 M NaCl, 0.1% Tween20, pH 7.6) for 30 min. 
Subsequently the blots were incubated for 24 h at 4°C with the respective primary 
antibodies (sections 6.3 and 7.3) in TBST buffer containing 5% (w/v) non-fat dry 
milk. Immunodetection was performed with peroxidise-conjugated rabbit anti-mouse 
(1:5000, abcam, Cambrige, UK) or goat anti-rabbit IgG-HRP(1:5000, Sigma, USA) 
secondary antibodies. Peroxidase activity was visualised using the ECL plus 
chemiluminescence system (Amersham Pharmacia, Freiburg, Germany) and exposed 
to Hyperfilm (Amersham Pharmacia, Freiburg, Germany). 
 
5.2.4 Flow Cytometry 
For analysis by flow cytometry cells were dissocitated and resuspended in 100 
µl PBS containing 0.5% (w/v) BSA and 2 mmol/L EDTA). Subsequently respective 
test and isotype control antibodies were added and incubated for 30 min at 4°C. At the 
end of incubation the cells were washed and analyzed on a BD FACS Calibur (Becton 
Dickinson). 
 
5.2.5 Immunocytochemistry 
Cells were plated in 24 well plates in stem cell-permissive medium and treated 
with 10 ng/ml of TGF-beta1, TGF-beta2, or both. Medium was changed twice weekly 
and supplemented with the corresponding TGF-beta concentrations. After 8 days, cells 
were fixed using 4% paraformaldehyde (PFA). Fixed cells were washed in TBS (0.15 
M NaCl, 0.1 M Tris-HCl, pH 7.5), then blocked with solution composed of TBS; 0.1% 
Triton-X100 (only for intracellular antigens); 1% bovine serum albumin (BSA) and 
0.2% Teleostean gelatin (Sigma, Taufkirchen, Germany) (Fish Skin Gelatine Buffer, 
FSGB). This solution was also used during the incubations with antibodies. Primary 
antibodies were applied overnight at 4°C. Alexa Fluor 488 (1:100, Molecular Probes, 
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Leiden, NL) species-specific secondary antibody was used for immuno-detection. 
Nuclei were counterstained using DAPI (1:10000, Sigma-Aldrich). Specimens were 
mounted on microscope slides using in Prolong Antifade kit (Molecular Probes, 
U.S.A.). Epifluorescence observation and photo-documentation were realized using a 
Leica microscope (Leica Mikroskopie und Systeme GmbH, Germany) equipped with a 
Spot™ digital camera (Diagnostic Instrument Inc, U.S.A.). 
 
5.2.6 Immunohistochemistry 
To determine expression of TGF-beta1, TGF-beta2, Olig 2, CD8, and CD68 
whole tissue sections of primary astrocytic GBM were subjected to immune-
histochemical analysis. These paraffin-embedded GBM samples were provided by the 
local department of Neuropathology in Aachen. In brief, 4 µm formalin-fixed paraffin-
embedded tissue sections were deparaffinized and immunostained after microwave-
based antigen retrieval: 
-TGF-beta1: 250 W, 32 min, citrate buffer (pH 7.2); TGF-beta2: 250 W, 32 min, 
neutral buffer followed by R&D: Antigen Retrieval Reagent-Universal (CTS 015) 
using the IView DAB Detection Kit on a Ventana Nexes autostainer (Ventana, 
Tucson, AZ, USA). Each antibody [TGF-beta1 (Acris; clone: DM 1047; mouse 
monoclonal; 1:200 dilution), TGF-beta2 (Santa Cruz: clone: sc-90; rabbit polyclonal; 
1:30 dilution)] was incubated for 32 min at room temperature. 
-CD8,  CD68: 600 W, 20 min, EDTA buffer; Olig 2: 600 W, 10 min, citrate buffer 
(pH 7.2) followed by blocking of endogeneous peroxidase (0.3 % H2O2, 30 min) and 
antibody incubation (CD8: C8/144B, DAKO, Denmark, undiluted; CD68: KP1, 
DAKO, Denmark, 1:1000; Olig 2, polyclonal, Sigma-Aldrich, Germany, 1:1250). 
Visualizing was performed using Vectastain Elite ABC Kit (Vector Laboratories, CA). 
 
5.2.7 Alamar Blue assay 
This assay measures the proliferation of cells. It is based on reduction-
oxidation reaction (REDOX) and incorporates a fluorometric/colorimetric REDOX 
indicator that fluoresces and changes color. The REDOX indicator is not toxic to cells 
and its reduction requires uptake by the cells. When cells in the medium grow, the 
metabolic activity results in chemical reduction of growth medium. This results in a 
reduced environment in the medium and when there is inhibition of growth, an 
oxidized environment is maintained. The reduction resulting from growth causes 
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REDOX indicator to change from oxidized (non-fluorescent, blue) form to reduced 
(fluorescent, red) form. Metabolic activity was measured using 10% AlamarBlue 
(Biosource, CA) that was added to the cell culture medium. The optical density was 
determined after 16 h at 590 nm and 540 nm. 
 
5.2.8 Animals and Genotyping 
B6.129S2-Trp53tm1Tyj/J heterozygous breeding pairs were obtained from 
Charles River and the experiments were performed on 10-14 weeks old mice. The 
genotypes were determined by tail clippings. The DNA was isolated and the PCR 
done using the primers 5'- ACA GCG TGG TGG TAC CTT AT -3'(oIMR036 - 
Common Primer), 5'- TAT ACT CAG AGC CGG CCT -3'(oIMR037 - WT Reverse), 
5'- CTA TCA GGA CAT AGC GTT GG -3'(oIMR038 - Mutant Reverse), yielding a 
fragment of 400 bp for p53+/+ and 600 bp for p53-/- mice. PCRs were perfomed with 50 
ng DNA using Hotstart Platinum Taq (Invitrogen) for 35 cycles (30 seconds at 94 °C, 
1 min at 66 °C, 1.5 min at 72 °C) and specific primers. 
 
 
5.3 Animal experiments 
 
5.3.1 Intracranial tumor assays 
Tumor cells were suspended in 2ul PBS and intracranially injected into T-
lymphocyte–deficient NMRI (nu/nu) mice. After general anaesthesia these aliquots 
were stereotactically injected into frontal cortex of 6- to 8-week-old mice. The 
injection coordinates were 3mm to the right of the midline, 2mm anterior to the 
coronal suture and 3mm deep. All procedures were conducted in accordance with 
German laws governing animal care (Az. 621-2531.1-04/03).  
 
5.3.2 Cryosectioning and Hematoxylin / Eosin staining 
Briefly mice were killed and their brains were removed and shock-frozen. 
10µm sections were prepared. Every fifth section was preserved and the sections in 
between were discarded. The object and the chamber temperature of the cryotome 
were maintained at -20°C. These sections were air-dried, acetone-fixed, and stained 
with haematoxylin-and-eosin. 
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For haematoxylin-and-eosin staining the slides were first fixed in ice cold 
acetone for 15 min and then air dried. The slides were then immersed in hematoxylin 
for 6 min and carefully washed with water. Excess water was drained and they were 
then immersed in eosin (0.25%) for 6 min. This was followed by careful washing with 
water. After this the slides were given 10 min each of ethanol wash in the following 
sequence-50% ethanol-1X, 70% ethanol-1X, 96% ethanol-2X, 100% ethanol 3X, 
Neoclear-3X. Slides were then air-dried for 2-3 min. Coverslips were then put after 
covering the stained sections with neomount. 
 
5.4 Bioinformatics and Statistics 
 
5.4.1 Bioinformatics 
As described in (Lottaz et al., 2010; Beier et al., 2012), data analysis was 
performed using the statistical computing environment R and the lifescience related 
extension Bioconductor. The expression values were background corrected and 
normalized using the robust multi-array average function implemented in the 
affymetrix package. A list of differentially expressed genes between TGF-beta1/2 
treated and untreated cell lines was compluted using linear models implemented in 
Bioconductor package limma. From these genes, the hundred genes showing the 
highest log fold change (FC) was selected. They all showed an absolute logFC bigger 
than 1.47. Based on these genes 80 GBM samples analyzed by Murat and coworkers 
(Murat et al., 2008), were clustered using complete linkage. Therefore Euclidean 
distances were computed between all samples based on only the 100 most 
differentially regulated genes after TGF-beta treatment. To evaluate the stability of the 
clustering consensus clustering was performed. The 24-gene signature described in 
Lottaz et al. 2010 (Lottaz et al., 2010) was also analyzed within the 80 GBM. 
Therefore consensus clustering was used again, but now only including the 24-
signature genes. Two expression indices were calculated per sample: one aggregating 
the expression across the 24-signature genes and the second aggregating the 
expression across the 100 TGF-beta responsive genes in single numbers. The indices 
were calculated by fitting a standard additive model with independent gene and 
sample effects using Tukey’s median polish procedure. A gene set of 134 innate 
immune response genes described by Murat and coworkers (Murat et al., 2008) for 
differential expression between tumor clusters was further examined. Differential 
52 
 
expression was assessed by calculating false discovery rates using the Benjamini-
Hochberg procedure implemented in the limma package. (This work was done by the 
Institute of Functional Genomics, University of Regensburg Medical School, Josef-
Engert-Strasse 9, 93053 Regensburg, Germany.) 
 
5.4.2 Stastistics 
Data analysis was performed using Graphpad Prism 5. The statistical tests used 
are indicated in the figure legends. All data are given as Mean and Standard Error of 
the Mean (SEM). A p-value <0.05 was considered significant. 
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6 Signature genes indicating different cells of origin of GBM CSC as guide for 
TGF-beta targeting therapies 
6.1 Abstract 
 Recent evidence suggesting the heterogeneity of GBM CSC posed the question 
for their rightful classification that may then allow to guide therapies targeting GBM 
CSC. It was earlier shown that GBM could be classified based on their transcriptional 
similarities to the putative cells of origin with Type I GBM showing similarities with 
fNSC and Type II GBM showing similarities with aNSC. In addition, the analysis of 
the transcriptional profile based on a 24-gene signature robustly identified GBM 
previously classified as either proneural or mesenchymal in vivo. The TGF-beta 
pathway emerged as the most differentially regulated pathway among the two groups. 
Here I show that similarity of CSC to either Type I or Type II CSC predicts the 
response to TGF-beta in vitro. In vivo, the similarity to the respective subtype 
determines the microenviroment of GBM as suggested by the strong association of the 
tumor infiltrating lymphocytes (TIL) and the Type II-like (mesenchymal) CSC 
subtype. Conversely, this may result in the failure of immune therapy in Type I 
(proneural) CSC. Taken together, these data provide a new rationale that may allow a 
selection of patients for therapies directed against TGF-beta and new immune 
therapies.  
 
6.2 Introduction 
Earlier bioinformatic analysis suggested that different putative cells of origin of 
CSC may give rise to different subtypes of GBM CSC (Lottaz et al., 2010). The 
expression patterns of 17 GBM CSC were compared with the expression patterns of 
various putative founder cells. Interestingly, the CSC always grouped with either 
fNSC or aNSC but not with any other putative founder cell. This analysis revealed two 
subtypes that were named as Type I and Type II. The Type I CSC was similar to the 
fNSC and the Type II CSC was similar to the aNSC. A 24-gene signature (based on 29 
transcripts) prospectively segregated the two subtypes. In vivo, these subtypes had 
similarities to the subtypes identified previously by Phillips and coworkers (Phillips et 
al., 2006). They named their subgroups according to the predominant physiologic 
functions of the signature genes as proneural, mesenchymal and proliferative (Phillips 
et al., 2006). However, only the proneural and mesenchymal but not the proliferative 
subtypes have been consistently reproduced by others. Type I CSC as identified by the 
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24-gene signature resembled the proneural subtype while Type II CSC resembled the 
mesenchymal subtype. The transcriptional analysis showed that the TGF-beta pathway 
is the most differentially regulated among the two types of CSC with aNSC-like CSC 
expressing TGF-beta associated transcripts that were downregulated in fNSC-like 
CSC. Interessting, fNSC have been been reported to be non-responsive to the effects 
to TGF-beta (Falk et al., 2008) while aNSC were responsive to TGF-beta (Wachs et 
al., 2006). This striking correlation led me to characterize the effects of TGF-beta in a 
panel of different Type I and Type II CSC lines and correlate the effects seen with 
their assignment to a given CSC subtype. Furthermore, I investigated the in vivo role 
of TGF-beta in multiple GBM to provide a new CSC-based rationale that may help to 
guide TGF-beta targeted therapies.  
 
6.3 Materials and Methods 
Preparation of primary GBM CSC culture 
Primary GBM CSC cultures were prepared from native tumor samples from 
GBM resections as described in 5.1.1. Samples were initially stored in sterile saline at 
4°C and cell lines were derived within 24 h after resection. CSC cultures were grown 
at 37°C in a humidified atmosphere of 95% air/5% CO2. If not otherwise stated, 50% 
of the culture medium was substituted twice weekly. In total 9 GBM CSC lines, R8, 
R11, R18, R28, R44, R49, R53, R54 and R58 were used for the current study. 
 
Preparation of CCL-64 culture  
CCL-64 cells are very sensitive to the presence of TGF-beta and were cultured 
to test the growth inhibition of these cells by TGF-beta. These cultures were 
maintained at 37°C in a humidified atmosphere of 95% air/5% CO2. Cell plating and 
treatment with various concentrations of TGF-beta were done as described in section 
5.1.2. 
 
Preparation of PBMC cultures 
PBMC were isolated from the blood of healthy volunteers as described in 
section 5.1.4. Freshly isolated PBMC were incubated at 37°C in complete medium and 
allowed to adhere for 1h in a 48 well plate at 37°C in a humidified atmosphere of 95% 
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air/5% CO2.  Only the non-adherent cells were collected for study and the adherent 
cells comprising the monocytes were discarded. 
 
Alamar Blue assay 
This reduction-oxidation based reaction was used to measure the proliferation 
of cells. Metabolic activity due to the growth of cells in a medium results in the 
chemical reduction of the growth medium. This results in a change of form of the 
REDOX indicator [from oxidized (non-fluorescent, blue) form to reduced (fluorescent, 
red) form)]. 10% Alamar Blue (Biosource, CA) was added to the cell culture medium 
and optical density was determined after 16 h at 590 nm and 540 nm. 
 
Clonogenicity Assay 
Cells were seeded as indicated in 96 well plates and treated with 10, 20 and 40 
ng/ml of TGF-beta1, TGF-beta2, or both. 10 wells with 50 cells were plated for every 
condition. Depending on the growth rate of various cell lines, the medium 
supplemented with TGF-beta was replaced weekly. At the end of 2-4 weeks the 
number of spheres/patches formed was determined. 
 
Quantitative real-time-PCR 
RNeasy kit (QIAGEN GmbH, Hilden, Germany) was used to extract RNA and 
cDNA was synthesized using the Reverse Transcription System (Promega GmbH, 
Mannheim, Germany). Real-Time-PCR was performed as described in section 5.2.1 
and the following primers pairs were used: 
Target Gene Forward Primer Sequence 
Reverse Primer sequence 
TGFBR2 5’- AGCAACTGCAGCATCACCTC -3’ 
5’-GCACTTTGGAGAAGCAGCATC-3’ 
TGF-beta1 5’-GGCGATACCTCAGCAACCGG-3’ 
5’- TCGGCGGCCGGTAGTGAACC-3’ 
TGF-beta2 5’- CACCATAAAGACAGGAACCTG - 3’ 
5’- GGAGGTGCCATCAATACCTGC -3’ 
18s-RNA 5’- CGGCTACCACATCCAAGGAA-3’ 
5’-GCTGGAATTACCGCGGCT-3’ 
Table 1. Primers used for quantitative real-time polymerase chain reaction 
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SDS-PAGE and Western blot 
For pSmad 2 protein analysis, cells were plated in 6 well plates and treated 
with 10ng/ml of each recombinant human TGF-beta1 (Peprotech) and recombinant 
human TGF-beta2 (Peprotech) for 0-60 min. Total cell lysates were prepared in the 
presence of Phosphatase Inhibitor Cocktail 1 (Sigma) according to the manufacturer’s 
instructions. For Western Blot analysis of TFGR2, TGF-beta2, and pSmad 2 protein 
expressions, 30-40 µg of total cell lysates were separated by 10-15% SDS-PAGE and 
transferred onto nitrocellulose membranes. The membranes were probed with 
antibodies against TGFBR2 (1:1000 Upstate), TGF-beta2 (1:1000 Santa Cruz 
Biotechnology), pSmad 2 (1:1000 Calbiochem) and beta-actin (1:5000, Abcam, 
Cambridge, UK) overnight at 4oC. Recombinant human TGF-beta2 (Peprotech) was 
used as positive control for the TGF-beta2 Western blot experiments. The detailed 
procedure is mentioned in the section 5.2.3. 
 
Flow Cytometry 
Cells were dissociated and resuspended in PBS containing 0.5% (w/v) BSA 
and 2 mmol/L EDTA). Cells were stained with mouse anti-human CD133/2-PE 
(clone293C3, Miltenyi Biotech) or the corresponding isotype control antibody 
(mIgG2b-PE; Caltag Laboratories). Cells were analyzed on a BD FACS Calibur 
(Becton Dickinson). 
 
Immunocytochemistry  
To compare the differential potential of the CSC lines in the presence and 
absence of TGF-beta, immunocytochemical analysis was performed. The detailed 
procedure is mentioned in section 5.2.5. The primary antibodies used were anti–β-
tubulin III (Promega), anti-GFAP (DAKO), anti-galactocerebroside C (Chemicon) and 
anti-nestin (Chemicon). Alexa Fluor 488 (1:100, Molecular Probes, Leiden, NL) 
species-specific secondary antibody was used for immuno-detection. Nuclei were 
counterstained using DAPI (1:10000, Sigma-Aldrich).  
 
Immunohistochemistry 
Expression of TGF-beta1 (Acris; clone: DM 1047; mouse monoclonal; 1:200 
dilution), TGF-beta2 (Santa Cruz: clone: sc-90; rabbit polyclonal; 1:30 dilution), Olig 
2 (polyclonal, Sigma-Aldrich, Germany, 1:1250), CD8 (C8/144B, DAKO, Denmark,  
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undiluted), and CD68 (KP1, DAKO, Denmark, 1:1000) in whole tissue sections of 
primary astrocytic GBM was determined by immune-histochemical analysis (Section 
5.2.6). 
 
Intracranial tumor assays 
T-lymphocyte-deficient NMRI (nu/nu) mice were used for the intracranial 
tumor assays. Tumors cells suspended in 2ul PBS were stereotactically injected into 
frontal cortex of 6- to 8-week-old mice. The injection coordinates were 3mm to the 
right of the midline, 2mm anterior to the coronal suture and 3mm deep and the 
procedure was followed after general anaesthesia.  
 
Cryosectioning and Hematoxylin / Eosin staining 
10µm sections were prepared from brains of mice and every fifth section was 
preserved. These sections were air-dried, acetone-fixed and finally stained with 
haematoxylin-and-eosin. The slides were first fixed in ice cold acetone for 15 min for 
haematoxylin-and-eosin staining and then passed through the steps as mentioned in 
section 5.3.2. 
 
Bioinformatics  
Statistical computing environment R and Bioconductor were used to analyze 
data. The robust multi-array average function from Affymetrix was used for 
background correction and normalization of data. Details have been provided in 
section 5.4.1. 
 
Stastistics 
Data analysis was performed using Graphpad Prism 5. The statistical tests used 
are indicated in the figure legends. All data are given as Mean and Standard Error of 
the Mean (SEM). The statistical significance was assessed using the t-test. A p-value 
<0.05 was considered significant. 
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6.4 Results  
a) Expression of TGF-beta receptor 2 determines TGF-beta responsiveness of 
CSC lines. 
The expression profile analysis showed that the TGF-beta signaling was the 
major signaling pathway difference between Type I and Type II CSC. I therefore 
checked if this in silico finding is true in vitro and in vivo also. The in vivo 
experiments involved intracranial injections of TGF-beta treated and untreated 
CSC in mice and the subsequent measurement of tumor volume by hematoxylin 
and eosin staining. This is a powerful system to measure tumor volume and the 
results are comparable to those obtained from magnetic resonance imaging (Pillai 
et al., 2011). 
I started by checking the response of various CSC lines to TGF-beta. For this I 
incubated 9 GBM CSC lines with various concentrations of TGF-beta1, TGF-
beta2 and both. This resulted in heterogeneous responses of the cell lines with 6 
(R11, R18, R28, R44, R54, R58) cell lines being completely resistant to TGF-beta 
incubation and not showing any change in growth pattern (Fig. 6A). In contrast, 3 
(R8, R53 and R49) of the cell lines showed changes of growth pattern (Fig. 10A). 
The 6 non-responsive cell lines did not show any change in sphere size (Fig. 6B) 
or clonogenicity (Fig. 6C) in response to incubation with TGF-beta.  
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Figure 6. Non-responsiveness of 6 GBM CSC lines. (A) Representative pictures 
of the non-responsive cell lines with and without TGF-beta1 and 2. (B) Relative 
sphere size of the non-responsive cells lines with and without incubation with 
10ng/ml of TGF-beta1 and 2. There was no significant difference between the 
sphere size of untreated and TGF-beta1/2 treated cells (two-sided t-test). (C) 
Relative clonogenicity of non-responsive cell lines with and without incubation 
with 10ng/ml of TGF-beta1 and 2. There was no significant difference between the 
clonogenicity of untreated and TGF-beta1/2 treated cells (two-sided t-test). 
 
To determine the molecular mechanism responsible for the varied response, I 
first checked if Smad2 was phosphorylated after the administration of TGF-beta1 
and 2 (10ng/ml). This revealed a time-dependent Smad2 phosphorylation in 4 out 
of 9 CSC lines (Fig. 7). Interestingly, there was no autocrine Smad2 
phosphorylation in any of the cell lines.  
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Figure 7. Time dependent Smad2 phosphorylation. 9 GBM CSC lines were 
incubated with 10ng/ml of TGF-beta1 and 2 and Smad2 phosphorylation was 
checked at 10, 30 and 60 min. Actin was used as loading control.  
 
The non-responsive cell lines showing absence of time-dependent Smad2 
phophorylation had lower TGFBR2 mRNA expression levels (Fig. 8A). The 
western blots also showed lower expression levels of TGFBR2 for the non-
responsive lines (Fig. 8B). 
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Figure 8. TGFBR2 expression determines the responsiveness of CSC towards 
TGF-beta.  (A) Relative mRNA expression of TGFBR2 normalized to 18S RNA 
in CSC lines with and without Smad2 phosphorylation (*p=0.04; one-sided t-test). 
(B) Immunoblotting for the detection of TGFBR2 in the whole cell lysates from 
various cell lines.  
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There was no detection of active TGF-beta in the western blots although 3 of 
the 9 CSC lines showed the expression of pro-TGF-beta (Fig. 9A). TGF-beta1 and 
2 mRNA was detected in all of the CSC lines (Fig. 9B). Thus the lack of TGFBR2 
was responsible for the resistance of 6 cell lines towards TGF-beta. Also, active 
TGF-beta was not present in the cell culture answering for the lack of autocrine 
Smad2 signaling in all the cell lines. 
 
A B
 
Figure 9. Lack of active TGF-beta production by the CSC lines. (A) 
Immunoblotting for the detection of active TGF-beta (12.5kD) in the whole cell 
lysates from various cell lines. (B) Relative mRNA expression of TGF-beta1 and 2 
normalized to 18S RNA. 
 
b) Characterization of TGF-beta induced effects on susceptible CSC lines. 
I went on to identify the effect of TGF-beta on the 3 responsive cell lines (R8, 
R49 and R53). 3 of the 4 CSC lines with TGFBR2 expression and Smad2 
phosphorylation showed varied response in migration (Fig. 10A) and proliferation 
(Fig. 10B) in response to TGF-beta. Two of the cell lines (R8 and R53) showed 
inhibition of proliferation and migration whereas R49 showed an increase in 
proliferation and migration.  
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Figure 10. CSC lines susceptible to TGF-beta respond heterogeneously. (A) 
Change in growth pattern of susceptible lines (R8, R49 and R53) after incubation 
with 10ng/ml of TGF-beta1 and 2 for 7 days. (B) 5000 cells were seeded in a 96-
well plate and incubated with 10ng/ml of TGF-beta1 and 2. After 7 days, 
proliferation was measured in terms of optical densitiy (OD) by incubating with 
Alamar Blue.  
  
The incubation of the responsive cell lines (R8, R49 and R53) with TGF-beta 
failed to modulate any bona fide stem cell properties. TGF-beta neither modulate 
the percentage of clonogenic cells nor did it change the expression of stem cell 
markers (Fig. 11A, B) and the spontaneous differentiation of these lines into the 
different neural lineages (Fig. 11B). Notably, there was no difference in the 
biological effects seen after treatment with TGF-beta 1, 2 or both.  
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Figure 11. No effect of TGF-beta in the stem cell compartment. (A) Effect of 
10ng/ml each of TGF-beta1 and 2 incubation on the CD133 content of R49 cell 
line is shown. (B) R8, R49 and R53 CSC lines were subjected to differentiation 
conditions in the presence of 10ng/ml of TGF-beta1 and 2 for 7 days. The changes 
in differentiation pattern compared to the control conditions are given. The 
markers used were Nestin (Stem cell), Tubulin (neuronal), GFAP (glia) and GalC 
(oligodendrocyte).  
 
Surprisingly, incubation of the CSC lines R11 did not induce any change of the 
cellular behavior despite of TGFBR2 expression and Smad2 phosphorylation. 
There was neither a change in clonogenicity (Fig. 12A) nor in migration and 
growth pattern (Fig. 12B).  Recently it was described that the TGF-beta-Leukemia 
Inhibitory Factor (LIF) axis could be crucial in regulating the self-renewal capacity 
of GBM CSC through the JAK-STAT pathway (Penuelas et al., 2009). I wanted to 
check if this TGF-beta-LIF axis was active in R11 cell line as it could be the 
reason for its resistance to TGF-beta. As my CSC lines are routinely cultured in 
medium supplement with LIF the effect of TGF-beta incubation could simply be 
overcome by the presence of LIF in media. So I incubated R11 with TGF-beta 
with and without the presence of LIF in media. There was an increase in 
clonogenicity in response to TGF-beta in the media lacking LIF but no difference 
was observed in media with LIF (Fig. 12C). This answered the seemingly aberrant 
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behavior of R11 and also confirmed the presence of TGF-beta-LIF axis in CSC 
lines. 
 
                                         
A
 
 
B
Untreated TGF-beta 1/2
R11
1m m 1m m
C
 
Figure 12. Effect of TGF-beta on the cell line R11. (A) 10 cells were plated in a 
96-well plate and incubated with TGF-beta. At the end of 14-42 days depending 
on their rate of proliferation the number of spheres/patches was counted. The 
number of clones at various concentration of TGF-beta2 in CSC showing 
phosphorylation of Smad2 is depicted. (B) Growth pattern of R11 cell line after 
incubation with 10ng/ml of TGF-beta1 and 2 for 7 days. (C) Change in 
clonogenicity of R11 cell line in medium with and without LIF is given. Varying 
concentrations of TGF-beta1 and 2 was used. 
 
The in vitro effects of TGF-beta were checked in vivo also. R8 and R49 cell 
lines were treated with TGF-beta for a week and then intracranially implanted into 
immune-compromised nude mice. Cells lacking any treatment were also implanted 
as controls. 10 weeks later the mice were sacrificed and checked for tumors. This 
resulted in formation of tumors in all the mice subjected to injections. The tumors 
formed by R8 untreated cells were smaller compared to R49 untreated cells (Fig. 
13 A, B). Also, the lesions of R8 cells pre-treated with TGF-beta were smaller 
compared to untreated cells. In contrast the lesions formed by R49 cells pre-treated 
with TGF-beta were of larger volume compared to the control tumors. This proved 
both, the in vitro and in vivo heterogeneity in response to TGF-beta treatment of 
CSC lines.                     
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Figure 13. Biological effects of TGF-beta incubation in susceptible CSC lines. 
(A, B)  R49 and R8 cells were incubated with 10ng/ml of TGF-beta1and 2 for 7 
days and injected intracranially in immune-compromised mice. The tumor 
volumes (A) of R49 and R8 and the representative pictures (B) are shown (p-
values: two-sided t-test). 
 
c) Inverse correlation between TGF-beta induced transcripts and markers of 
innate immune response. 
For the verification of this hypothesis, R8 and R53 cell lines were incubated 
with TGF-beta for 72 h and the induced transcripts were identified by microarray. 
The 100 most differentially regulated genes were then identified. This set of genes 
was then used to identify GBM that show TGF-beta induced transcripts. 
Microarray data from 80 homogeneous and well characterized GBM (Murat et al., 
2008) were used to identify GBM showing the presence of TGF-beta induced 
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transcripts. Two distinct clusters resulted from this, one having the presence of 
TGF-beta induced transcripts (further referred to as TGF-beta+ cluster) and the 
other lacking TGF-beta induced transcripts (further referred to as TGF-beta- 
cluster) and this was based on the 100 most differentially regulated genes in 
response to TGF-beta (Fig. 14A). Of the 80 GBM analyzed only 22 fell in the 
TGF-beta+ cluster. Thus, it was obvious that in most of the GBM TGF-beta 
signaling is not active. This was validated by consensus clustering (Fig. 14B).  
 
        
BA
 
Figure 14. Inverse expression of TGF-beta induced transcripts and innate 
immune response genes. (A) Segregation of 80 GBM described by Murat and 
group (Murat et al., 2008) as per the 100 most differentially regulated genes after 
TGF-beta incubation. (B) Verification of this result by consensus clustering.    
 
It had already been reported that fNSC are resistant to TGF-beta (Falk et al., 
2008) and another group had reported that the aNSC show proliferation arrest in 
response to TGF-beta (Wachs et al., 2006). A 24-gene signature was earlier 
described that separated GBM into two groups (Type I and Type II) based on their 
relationship to fetal or adult NSC (Lottaz et al., 2010). These two groups had genes 
of the TGF-beta signaling cascade as the most differentially regulated genes 
among them. Also, it was reported earlier that GBM subgroups exist expressing 
TGF-beta induced transcripts (Li et al., 2009a). Thus TGF-beta seemed to be the 
differentiating factor between Type I and Type II CSC and also subgroups of 
GBM as mentioned by Li and group (Li et al., 2009a). These observations led me 
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to explore if there is any correlation between transcriptional similarities either to 
fetal or adult NSC-like GBM and the expression of TGF-beta induced transcripts. 
The same analysis steps were used as for the 100 TGF-beta induced genes and the 
same set of 80 GBM was clustered based on 24 cells of origin genes. This resulted 
in two clusters (Fig. 15A) and the stability of the clusters was again proved by 
analysis of consensus clusters (Fig. 15B). The first cluster comprised Type II CSC 
and showed 24 gene expression levels typical of aNSC whereas Type I CSC 
comprised the second cluster and its 24 gene expression levels was similar to that 
of fNSC. To compare the expression of genes in the ‘‘TGF-beta target”-gene set to 
the “cell of origin”-gene set, two expression indices were calculated. These 
expression indices aggregated the coherent expression of genes in the respective 
gene sets to one single number per GBM. In Figure 15A, GBM are sorted by these 
indices in increasing order. There was a strong inverse correlation (r=-0.885) 
between the TGF-beta target index and the cell of origin index. Majority of TGF-
beta responsive GBM show a high cell of origin index pointing to their origin from 
(TGF-beta responsive) aNSC. Similarly most of the TGF-beta resistant GBM 
show a low cell of origin index suggesting their origin from (TGF-beta resistant) 
fNSC. Taken together, the fNSC-like (Type I) and aNSC-like (Type II) CSC could 
be distinguished by their differential response to TGF-beta. 
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Figure 15. Cluster comparisons and validation. (A) Comparison of clustering 
based on TGF-beta target gene index and 24 cell of origin gene index. (B) 
Verification of this result by consensus clustering. 
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d) Signature genes indicating similarity to fetal or adult NSC as guide for TGF-
beta targeting therapies.  
Now the in vitro responsiveness of the 9 GBM CSC was known and GBM 
could also be segregated based on TGF-beta target gene index and the cell-of-
origin index. So both the indices were applied to compare if one of the indices 
could better segregate the GBM into the two types i.e. Type I and Type II. The 
TGF-beta target gene index could not correctly identify the Type II i.e. the 
responsive cell lines. However the 24 gene cell of origin index reliably 
distinguished the Type I and II CSC (Fig. 16A). This was confirmed by correlating 
the change in proliferation in response to TGF-beta treatment (Fig. 16B) with the 
24 signature gene index. Thus the 24 gene signature can be used to identify the 
responsiveness of GBM CSC in vivo and it can also predict the presence of TGF-
beta in vivo in the tumor surroundings. Therefore this signature can further be used 
to identify patients who would benefit from TGF-beta targeting therapies.  
     
BA
 
Figure 16.   Relationship to fNSC or aNSC predicts the response to TGF-beta 
(A) Clustering based on the 24 cell of origin gene signature identifies two groups 
of GBM with contrasting expressions of TGF-beta induced transcripts. (B) 
Correlation of the gene expression index based on relation to cell of origin and 
proliferation response to TGF-beta. 
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e) TGF-beta expression correlates with the absence of immunological infiltrates 
in proneural Type I CSC-like GBM. 
As there was complete lack of TGF-beta production by the GBM CSC it was 
checked if the tumor surroundings showed the presence of the same. There have 
been multiple reports about TGF-beta production by microglia (Ekdahl et al., 
2009) or other factors of tumor niche. Immunohistochemical analysis of 19 GBM 
tumor sections revealed varialble TGF-beta1 and 2 expressions (Fig. 17A). To 
study this, the microarray data by Murat and coworkers was checked again (Murat 
et al., 2008). They had identified 134 genes associated with innate immune 
response. The expression of these genes was studied in relation to TGF-beta+/- 
clusters as identified by the 24 gene signature (Fig. 17B). Of these 134 genes, 27 
were identified as differentially regulated among the two clusters with a false 
discovery rate below 0.05. These genes showed lower expression levels in TGF-
beta- cluster (Type I CSC) compared to TGF-beta+ cluster (Type II CSC) 
suggesting a correlation between TGF-beta induced genes, CSC subtype and 
innate immune response. However, to further validate the array data the infiltration 
of immune cells in 19 primary GBM samples and the expression of key molecules 
for Type I or Type II CSC was studied. 
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Figure 17. Presence of active TGF-beta in patient tumor samples. (A) 
Immunostaining of TGF-beta1 and 2 in tumor sections. (B) Clustering of 134 
innate immune response genes [ identified by Murat and coworkers (Murat et al., 
2008)] and relation to TGF-beta +/- clusters. 
 
Olig2 is a marker of Type I CSC in vitro and for proneural GBM in vivo and it 
is hardly expressed in mesenchymal GBM (Phillips et al., 2006). To correlate the 
amount of immune infiltration with the GBM subtype, the amount of infiltrating 
CD8 (cytotoxic T-lymphocytes) and CD68 (microglia) cells were measured and 
related to the presence or absence of Olig2 (Fig. 18A). Of the 19 GBM samples, 
11 showed strong expression of Olig2 and were thus classified as Type I-CSC like 
GBM. 5 showed moderate to low expression of Olig2 and were classified as Type 
II-like GBM. In line with the hypothesis there was an inverse correlation between 
the presence of Olig2 and the presence of CD8 and CD68 immune cells (Fig. 18B, 
C). Thus TGF-beta may suppress infiltrating immune cells in Type I CSC-like 
GBM.  
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Figure 18. Inverse correlation between TGF-beta expression and tumor 
infiltrating lymphocytes. (A) Expression of Olig2, CD8 and CD68 in Type I and 
Type II GBM. (B, C) Correlation between expression of Olig2 and CD8 (B) and 
CD68 (C). 
 
6.5 Discussion 
Recently it was reported that through bioinformatic analysis the CSC lines can 
be segregated into groups (Type I and Type II) and these groups have similarities to 
their putative cells of origin (fNSC and aNSC). This study resulted in segregation of 
CSC into groups which can be identified by a robust 24-gene signature. Furthermore, 
molecular difference between the groups was identified. It was decided to verify these 
findings in vivo. The results showed that the two groups can be identified by 
difference in TGF-beta signaling. TGF-beta is a versatile cytokine with a plethora of 
functions. Although role of TGF-beta in gliomas is very well studied, not much is 
known about its effect on GBM CSC.  
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There have been previous reports (Bruna et al., 2007) about the differential 
response to TGF-beta by primary cultured tumor cell lines (PCTC) where they showed 
that the proliferation of these PCTC could be inhibited, enhanced or remain unchanged 
when incubated with TGF-beta. TGF-beta was found to be promoting the proliferation 
in these cases by acting on unmethylated PDGF-B gene. The epigenetic status of the 
PDGF-B gene (methylated or unmethylated) determines if TGF-beta would be acting 
as an oncogenic factor. However, only a small number of GBM depend on PDGF 
signaling (Brennan et al., 2009). Thus the reason and consequences for heterogeneity 
remains mostly unexplained.  
The GBM CSC lines also showed heterogeneity in response to TGF-beta 
incubation. While some lines showed complete lack of response to TGF-beta 
incubation, some lines showed contrasting response. I found that the TGFBR2 
expression levels determined the responsiveness of my cell lines.  
Role of TGFBR2 as tumor suppressor have been established by expressing 
wildtype TGFBR2 in colon or breast carcinoma cells lacking functional TGFBR2 
allele (Sun et al., 1994; Wang et al., 1995), and by overexpressing it in thyroid 
carcinoma (Turco et al., 1999). TGFBR2 expression resulted in growth inhibition and 
significantly reduced tumor formation in nude mice. Furthermore, expression of 
dominant negative forms of TGFBR2 in skin or mammary gland increased tumor 
formation (Bottinger et al., 1997; Go et al., 1999). Corroborating these results, a 
correlation is seen between decreased expression of TGFBR2 and high grade of 
tumors in human cancers (Kim et al., 2000b) and various other experimental systems 
(Tang et al., 1999; Venkatasubbarao et al., 2000; Kim et al., 2001; Lee et al., 2001). 
Additionally, TGFBR2 mutations are very common in  gastric cancers (Park et al., 
1994b; Myeroff et al., 1995; Chung et al., 1996; Ohue et al., 1996), colon cancers 
(Markowitz et al., 1995; Myeroff et al., 1995; Lu et al., 1996) and gliomas (Izumoto et 
al., 1997) with microsatellite instability but are less common in microsatellite 
instability tumors from the pancreas, liver, endometrium and breast (Myeroff et al., 
1995; Vincent et al., 1996; Furuta et al., 1999; Kawate et al., 1999; Tomita et al., 
1999). Colon cancers which do not have microsatellite instability (Grady et al., 1999) 
and various other carcinomas have been shown to have missense and inactivating 
mutations in the kinase domain of TGFBRII (Reiss, 1999; Massague et al., 2000).  Of 
the 9 GBM CSC lines that I investigated, 6 lines that were non-responsive to TGF-beta 
incubation showed downregulation of TGFBR2 expression. In line with this, the non-
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responsive cell lines lacked time-dependent Smad2 phosphorylation whereas the 
responsive lines showed phosphorylation of Smad2. Interestingly, most tumors do not 
have inactivated TGFBR2 expressions, although this may provide a clear advantage 
for developing tumors. Though loss of TGF-beta signaling results in early onset of 
tumor due to the loss of growth inhibition by TGF-beta, it protects against tumor 
progression. Thus TGF-beta receptors act as tumor suppressors in the early stages of 
tumor development but at later stages TGF-beta signaling results in enhanced 
migration and invasion of tumor cells.  
Then it was checked if the GBM CSC produce TGF-beta as there had been 
multiple earlier reports of tumors overexpressing TGF-beta. Of the three different 
TGF-betas, Beta1, Beta2 and Beta3, TGF-beta1 has been found to be most frequently 
upregulated in tumor cells (Derynck et al., 1987; Dickson et al., 1987) . TGF-beta has 
numerous effects, the most important being the increase in invasiveness of tumor cells 
and changes in tumor microenvironment. An important phenomenon, epithelial to 
mesenchymal transformation (EMT) plays an important role in the metastasis of tumor 
cells (Thiery and Chopin, 1999). This phenomenon is observed not only during cancer 
progression but also during palatal (Kaartinen et al., 1995; Proetzel et al., 1995), 
cardiac (Potts and Runyan, 1989; Brown et al., 1999) and hair-follicle development 
(Weinberg et al., 1990).  Interestingly, I found that the GBM CSC does not produce 
active TGF-beta. Although I did detect pro-TGF beta production by the GBM CSC in 
vitro, active TGF-beta was absent. The TGF-beta protein is released in an inactive 
form and is bound to latent TGF-beta binding proteins (Miyazono et al., 1993; Munger 
et al., 1997; Oklu and Hesketh, 2000). This latent form has its advantages as it an 
important safeguard against accidental activation and may stabilize and direct the 
latent TGF-beta complex to ECM where it is stored (Taipale et al., 1998; Oklu and 
Hesketh, 2000). A well-regulated activation process for this complex is in place. This 
activation process is mediated by proteases that degrade the complex and release the 
highly stable active TGF-beta dimer. Plasminogen which is converted to plasmin at 
sites of cell migration and invasion (Andreasen et al., 1997) and plasmin has been 
found to activate latent TGF-beta (Sato and Rifkin, 1989; Lyons et al., 1990). 
Malignant cells frequently express MMP-2, MMP-9 at the sites of tumor invasion and 
they have been found to activate latent TGF-beta (Yu and Stamenkovic, 2000). Apart 
from proteases certain ECM proteins like thrombospondin have been found to activate 
latent TGF-beta (Schultz-Cherry and Murphy-Ullrich, 1993; Crawford et al., 1998). 
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The αvβ6 integrin expressed at the surface of epithelial cells in response to 
inflammation may mediate TGF-beta activation (Munger et al., 1999). These 
observations suggest the need and importance of cellular interaction to activate 
intratumoral TGF-beta.  
Although GBM CSC lines showed only the presence of unprocessed mRNA of 
TGF-beta1 and 2, the presence of active forms of both TGF-beta1 and 2 in the tumor 
samples was detected. One drawback with this was that I could not analyze the tumor 
sections from which the 9 GBM CSC lines of the present study were isolated and had 
to look for TGF-beta presence in fresh GBM sections. The presence of active TGF-
beta in the tumor samples further underscores the need for cellular interaction for 
activation of TGF-beta and also prompted me to investigate the need for the presence 
of TGF-beta in vivo. TGF-beta is a potent immunosuppressor. Tumors cells stimulate 
tumor development and progression by mitigating immune response through the 
secretion and activation of TGF-beta1. The proliferation and differentiation of T 
lymphocytes, lymphokine-activated killer cells, NK cells, neutrophils, macrophages 
and B-cells is inhibited by TGF-beta (Letterio and Roberts, 1998; Ashcroft, 1999; 
Fortunel et al., 2000). Enhanced expression of TGF-beta1 by tumor cells have been 
shown to increase tumorigenicity and also prevented the activation of cytoxic T-
lymphocyte function (Torre-Amione et al., 1990). This inhibition of cytoxic T-
lymphocyte was brought about by the repressive activity of TGF-beta on the 
expression and function of inteleukin-2 (IL-2) and its receptors (Kehrl et al., 1986a; 
Kehrl et al., 1986b). Ectopic expression of IL-2 in EMT6 mammary tumor cells 
lacking cytoxic T-lymphocyte response due to enhanced TGF-beta1 expression 
resulted in the rescue of the reponse (McAdam et al., 1994). TGF-beta1 induced 
immunosuppression of NK cells results in cancer progression (Arteaga et al., 1993; 
Arteaga et al., 1999). Furthermore, TGF-beta renders the tumor cells less 
immunogenic by massive downregulation of the expression of major 
histocompatibility complex (MHC) class II antigens (Czarniecki et al., 1988; Geiser et 
al., 1993; Letterio et al., 1996). 
Therefore the presence of tumor infiltrating immune cells in the GBM samples 
was checked. As expected, the infiltration of GBM with immune cells substantially 
differed between the tumors. This prompted me to inspect if there is a pattern to this 
immune infiltration and if there is one, could it be predicted using markers for the two 
CSC subtypes. I found that the Type-I-like (proneural) subtype CSC showed a 
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significantly reduced immune cell infiltration. In contrast, the Type II-like 
(mesenchymal) subtype CSC showed comparatively more immune cell infiltration. 
This was in line with the almost complete TGF-beta resistance of the proneural 
subtype CSC lines and suggests that TGF-beta mainly suppresses infiltrating immune 
cells in Type I CSC-like (proneural) GBM but hardly modulates TGF-beta resistant 
CSC.  One would therefore predict, that Type I CSC-like GBM do not respond to 
therapies aiming to stimulate an antitumor immune response.  
In a recent study supporting this prediction, it was shown that the mesenchymal 
subtypes are more susceptible to dendritic cell vaccination compared to the proneural 
ones (Prins et al., 2010). Interestingly and in line with the oncogenic role of TGF-beta 
it was shown that tumors with low TGF-beta2 expression levels are more prone to 
dendritic cell vaccination (Liau et al., 2005). I here provide the missing link that may 
explain these phenomena identified in these clinical trials.  The newly identified 24 
gene signature may now help to successfully identify the Type I CSC-like proneural 
and Type II CSC-like mesenchymal subtypes. The higher TGF-beta expression levels 
in the Type I CSC-like proneural subtypes subdue the expression of innate immune 
response of the patients thus maintaining and probably promoting tumor progression.  
This is a crucial finding as it paves the way for the accurate identification of 
tumors to be targeted either by anti-TGF or immune therapy. This will also throw light 
on the role of TGF-beta in immune escape and also how different tumors employ 
different mechanisms for growth, thus making each susceptible to a particular therapy. 
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7 Impaired TGF-beta signaling– an early step in the genesis of glioblastoma 
cancer stem cells 
7.1 Abstract 
TGF-beta and p53 are well established mediators of malignancy in GBM. 
However, it remains unknown if and when these two signaling systems interact during 
the genesis of GBM.  Mice with inactive p53 develop a hyperplastic SVZ that do not 
transform into glioma and therefore correspond to a premaligant lesion of GBM. Here 
I investigated the effect of TGF-beta in the SVZ cells of mice lacking p53. This was 
done using NSC isolated from SVZ of mice which were homozygous, heterozygous, 
or had inactive p53 gene. Wildtype NSC showed proliferation arrest in response to 
TGF-beta incubation. In contrast, in the mutant cells lacking p53 gene, there was no 
response to TGF-beta although the canonical components of the TGF-beta pathway 
were intact. This indicates that p53 is a crucial cofactor required for TGF-beta 
mediated cell cycle arrest in NSC. Blocking the TGF-beta signaling resulted in 
enhanced proliferation in wildtype cells but not in mutant cells suggesting TGF-beta 
autocrine signaling in wildtype NSC. In summary, these data suggest that loss of p53 
results in lack of response to TGF-beta leading to enhanced proliferation of SVZ NSC. 
 
7.2 Introduction 
 Direct p53 mutations are frequent in low grade gliomas, secondary 
Glioblastoma and malignant gliomas. However almost all glial tumors display 
alterations of p53 function, e.g. MDM2 amplification (Louis, 1994; Nozaki et al., 
1999) indicating that p53 mutations are required for the genesis of GBM. P53 is 
among the most intensively studied proteins and its role has been established in 
multitude of cellular processes including apoptosis, differentiation, proliferation, 
senescence and cell cycle (Vousden and Prives, 2009). Recently there have been 
reports of p53 involvement in self-renewal of stem cells (Zhao and Xu, 2010). This 
adds a novel level of complexity to the p53 role. 
 Also, loss of p53 results in enhanced proliferation of neural stem or progenitor 
cells. Notably, this loss does not result in tumor formation and this function may be 
compensated by alternative pathways or the mice does not survive until glioma 
formation (Gil-Perotin et al., 2006) indicating that the hyperplastic SVZ actually 
correspond to premalignant lesions. In animal model of glioma, loss of p53 cooperates 
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with PTEN (Zheng et al., 2008b, 2008a) or NF1 (Zhu et al., 2005) loss to form 
gliomas. Glioma formation is also seen when Ras (Lee et al., 2008) or PDGF (Hede et 
al., 2009) is overexpressed in a p53 null background. Thus p53 loss in itself does not 
lead to transformation. Although these data indicate, that additional stimulus inducing 
proliferation is needed to from gliomas, it remains unknown why p53 induces an 
increased proliferation of NSC resulting in an increased cell number in the SVZ. 
 The canonical TGF-beta signaling results in the formation and nuclear 
translocation of Smad2/4 dimers. However, additional factors were required to initiate 
transcription. P53 is an established cofactor required to regulate cell cycle by 
induction of p21cip/waf. As described above, TGF-beta1 strongly suppresses the 
proliferation of adult NSC in mice. Given that most of GBM CSC were non-
responsive to TGF-beta (see above), it remains unknown if and when premalignant 
and malignant NSC actually lose TGF-beta responsiveness. The working hypothesis of 
this subproject therefore suggests that the anti-proliferative control of TGF-beta in 
NSC is lost in p53 null background. If so, this could be one of the early steps in the 
origin of GBM and could give a clue on the initiation of GBM. 
 
7.3 Materials and Methods  
Animals and Genotyping 
 Experiments were performed on 10-14 weeks old B6.129S2-Trp53tm1Tyj/J 
heterozygous breeding pairs of mice. Tail clippings were done to determine the 
genotypes. Following primers were used to for PCR with DNA isolated from the tail 
clippings: 5'- ACA GCG TGG TGG TAC CTT AT -3'(oIMR036 - Common Primer), 
5'- TAT ACT CAG AGC CGG CCT -3'(oIMR037 - Wildtype Reverse), 5'- CTA TCA 
GGA CAT AGC GTT GG -3'(oIMR038 - Mutant Reverse). This resulted in fragments 
of 400 bp for p53+/+ and 600 bp for p53-/- mice. PCR was performed with 50 ng of 
DNA for 35 cycles (30 seconds at 94 °C, 1 min at 66 °C, 1.5 min at 72 °C) and 
specific primers. 
 
Neural Stem Cell culture 
Tissue from SVZ isolated from 2-4 month-old mice was homogenized and 
cells were resuspended in NB medium (Gibco BRL, Germany) as mentioned in 
section 5.1.2. These cultures were maintained at 37 °C in a humidified incubator with 
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5% CO2. Cells were passaged by using accutase (PAA, Austria) and a total of 5 x 105 
cells were seeded in a T75 flask (TPP, Switzerland). 
 
Reverse Transcriptase PCR 
Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen, 
Germany) following the manufacturer’s instructions. The purity of the extracted RNA 
was determined by measuring the optical density at wavelengths of 260 and 280 nm 
using standard spectrophotometer. 1µg of total RNA was used to synthesize single 
stranded c-DNAs using reverse transcription kit (Promega, USA). PCRs were 
performed for 30 cycles (30 seconds at 94 °C, 2 min at 66 °C and 1 min at 72 °C ) 
using the following primers: 
Target 
Gene 
Forward Primer Sequence 
Reverse Primer Sequence 
Smad 2 5'- AGTATTAACTCAGATGGGATCCCCTTC – 3' 
5'- CTTTAATTGATGAGACCTCAAGTGCTG -3' 
Smad 7 5'- TTTGCCTCGGACAGCTCAATTCGG -3' 
5'- CTCGTAGTCGAAAGCCTTGATGGAG -3' 
Table 2. Primers used for reverse transcriptase polymerase chain reaction  
PCR products were analysed on 1% agarose gel and visualized with Ethidium 
Bromide staining. Amplified house keeping gene beta-actin was used as loading 
control. 
SDS-PAGE and Western blot analysis 
Phospho-Smad 2 protein analysis was done by plating cells in 6 well plates and 
treating  with 10ng/ml of each recombinant human TGF-beta1 (Peprotech) and 
recombinant human TGF-beta2 (Peprotech) for 0-60 min. Total cell lysates were 
prepared in the presence of Phosphatase Inhibitor Cocktail 1 (Sigma) according to the 
manufacturer’s instructions. P21 western blot analysis was done by incubating cells 
with 10ng/ml of each recombinant human TGF-beta1 (Peprotech) and recombinant 
human TGF-beta2 (Peprotech) for 0-72 hr. For Western Blot analysis of TFGR2, p21 
and pSmad 2 protein expressions, 20-30 µg of total cell lysates were separated by 10-
15% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes 
were probed with antibodies against TGFBR2 (1:1000 Upstate), p21 (1:1000 Santa 
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Cruz Biotechnology), pSmad 2 (1:1000 Calbiochem) and beta-actin (1:5000, Abcam, 
Cambridge, UK) overnight at 4 oC.  
 
Alamar Blue assay 
This assay measures the proliferation of cells. It is based on oxidation-
reduction reaction (REDOX) and incorporates a fluorometric/colorimetric REDOX 
indicator that fluoresces and changes color .The REDOX indicator is not toxic to cells 
and its reduction requires uptake by the cells. When cells in the medium grow the 
metabolic activity results in chemical reduction of growth medium. This results in a 
reduced environment in the medium and when there is inhibition of growth, an 
oxidized environment is maintained. The reduction resulting from growth causes 
REDOX indicator to change from oxidized (non-fluorescent, blue) form to reduced 
(fluorescent, red) form. 
 
Clonogenicity Assay 
Cells were seeded as indicated in 96 well plates and treated with 10 ng/ml of 
TGF-beta1, TGF-beta2 or both. 10 wells with 50 cells were plated for every condition. 
Depending on the growth rate of various cell lines, the medium supplemented with 
TGF-beta was replaced weekly. At the end of 1-2 weeks the number of 
spheres/patches formed was determined. 
 
Immunocytochemistry  
Cells were plated in 24 well plates in neurobasal medium. After 5 days, cells 
were fixed using 4% PFA. Fixed cells were washed in TBS (0.15 M NaCl, 0.1 M Tris-
HCl, pH 7.5), then blocked with solution composed of TBS; 0.1% Triton-X100 (only 
for intracellular antigens); 1% bovine serum albumin (BSA) and 0.2% Teleostean 
gelatin (Sigma, Taufkirchen, Germany) (Fish Skin Gelatine Buffer, FSGB). This 
solution was also used during the incubations with antibodies. Smad2 primary 
antibody (1:1000 Santa Cruz, USA) was applied overnight at 4°C. Stainings were 
visualized using anti-rabbit Alexa Fluor 488 (1:100, Molecular Probes, Leiden, NL) 
conjugates.Nuclei were counterstained using DAPI (1:10000, Sigma-Aldrich). 
Specimens were mounted on microscope slides using in Prolong Antifade kit 
(Molecular Probes, U.S.A.). Epifluorescence observation and photo-documentation 
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were realized using a Leica microscope (Leica Mikroskopie und Systeme GmbH, 
Germany) equipped with a Spot™ digital camera (Diagnostic Instrument Inc, U.S.A.).  
 
Stastistics 
 Data analysis was performed using Graphpad Prism 5. The statistical tests used 
are indicated in the figure legends. All data are given as Mean and Standard Error of 
the Mean (SEM). The statistical significance was assessed using the t-test. A p-value 
<0.05 was considered significant. 
 
7.4 Results  
a) The mutant cells showed more proliferation compared to wildtype cells and were 
non-responsive to TGF-beta treatment. 
I carried out these experiments to study the interaction of p53 in the 
transduction of TGF-beta signal. Initially the morphology of the cells with and without 
p53 was studied. Then the effects of TGF-beta on wildtype (p53+/+) and mutant (p53-/-) 
cells lines, further on referred to as wildtype and mutant cell lines were characterized 
in 2 different NSC lines each. Plating of single cells of both cell types resulted in 
comparatively much larger neurospheres in case of mutant cells (Fig. 19A). It had 
been reported earlier that the p53-/- cells proliferated more compared to p53+/+ cells 
(Gil-Perotin et al., 2006). In my hands, a similar increase of the growth rate was 
observed (Fig. 19B). The increase in size of neurosphere was in line with an increase 
in the amplification rate (i.e. number of viable cells after 5 days in culture) of the same 
(Fig. 19C).  
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Figure  19. Enhanced proliferation of mutant cells. (A) Representative images of 
neurospheres formed from wildtype and mutant cells after 5 days in culture. (B) 
Comparison of the neurosphere size from wildtype and mutant cells. (C) Higher 
amplification rate (Number of viable cells divided by the number of cells plated) in 
mutant cell line. 
 
To study the effect of TGF-beta, on day one the cells were plated and the 
following day they were treated with TGF-beta1 and 2. In conformation of the 
published reports the wildtype lines showed inhibition of proliferation as evident by 
their metabolic activity measurement by Alamar Blue. Interestingly and in contrast, 
the mutant cells showed higher proliferation and were almost resistant to the anti-
proliferative TGF-beta effect (Fig. 20 A, B). Notably, the mutant cells when cultured 
for an extended duration (for eg. when under TGF-beta incubation – Incubation with 
TGF-beta may require that the cells are not passaged for 14-21 days with only regular 
changes of the cell-culture media) tended to have an adherent growth profile unlike 
wildtype cells which retained their neurosphere forming ability.   
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Figure 20. Non-responsiveness of mutant (p53-/-) cells to TGF-beta. (A) 
Representative images depicting the growth pattern of cells with and without TGF-
beta. 10ng/ml of TGF-beta1 and 2 was used for incubation. (B) Measurement of 
proliferation in the presence of 10ng/ml of TGF-beta1 and 2. (**p<0.01, ***p<0.001). 
 
b) The p53 mutant cell lines resisted TGF-beta growth arrest even though the 
components of TGF-beta signaling pathways were intact. 
For the GBM CSC the lack of response to TGF-beta was due to the absence of 
TGFBR2 so its presence was checked first in these cell lines. TGFBR2 was detected n 
all the cell lines irrespective of the genetic background (Fig. 21A). The presence of the 
downstream signaling components Smad2 and Smad 7 was then checked (Fig. 21B). 
These components too were present in all the cell lines.   
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Figure 21. Loss of response in mutant cells even though the components of 
canonical TGF-beta pathway are intact. (A) Western blot analysis for the 
expression of TGFBR2. (B) Detection of Smad2 and Smad7 by PCR.  
 
To check if the Smad signaling was functional and similar in all the cell lines I 
carried out time-dependent phosphorylation of Smad2 for all the cell lines. Cells were 
incubated with 25ng/ml of TGF-beta1 and 2 for 10, 30 and 60 min and checked for 
Smad2 phophorylation. There was uniformity in the results as all the cell lines showed 
time-dependent Smad2 phosphorylation (Fig. 22A, B). Also, there was no autocrine 
Smad2 signaling evident from lack of phosphorylation in the untreated cells. 
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Figure  22. Time dependent Smad2 phosphorylation. (A, B) Cells were incubated 
with 10 ng/ml of TGF-beta1 and 2 and checked for phosphorylation of Smad2 at 0, 10, 
30 and 60 min. 
 
Smad2 was also present in the cytoplasm of cells from all the cell lines (Fig. 
23). To determine if the anti-proliferative check of TGF-beta was intact, I checked for 
the presence of p21 in time-dependent manner at 24, 48 and 72 hrs time points. In line 
with the previous results the wildtype cells showed activation of p21 on TGF-beta 
incubation. In contrast, this was lacking in the mutant cell lines (Fig. 24 A, B). 
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Figure 23. Detection of Smad2 in the cytoplasm. Immunohistochemical analysis for 
the presence of Smad2 in the cytoplasm with and without 10ng/ml of TGF-beta1 and 
2. DAPI was used as nuclear counterstain. 
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Figure 24. Time dependent phosphorylation of p21. (A, B) Induction of p21 at 
multiple time-points (0, 24, 48 and 72 hours) after incubation with 10ng/ml of TGF-
beta1 and 2. Beta- actin was used as loading control.  
85 
 
c) TGF-beta had no effect on the clonogenicity. 
To check if the effect of TGF-beta was on the stem cell compartment, 10 cells/well 
were plated in 96 well plates and treated with TGF-beta1, 2 and both for 14-21 days. 
Given the inferences of the different growth pattern of mutant and wildtype NSC, I 
plated single cells and counted clonogenic cells irrespective if they grew as spheres or 
adherent patches. As described above, the mutant cells formed more number of 
spheres/patches compared to the wildtype cells both with and without TGF-beta (Fig. 
25). However, there was no significant difference in clonogenic growth between the 
TGF-beta treated and control cells irrespective of the p53 status of the cells.  
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Figure 25. No effect of TGF-beta on clonogenicity. Wildtype and mutant cells 
were treated with 10ng/ml of TGF-beta1 and 2 for 14-21 days and clonogenicity 
was determined. 
 
d) Blockade of TGF-beta signaling in wildtype cells resulted in enhanced 
proliferation whereas mutant NSC were unaffected. 
As per my hypothesis the wildtype cells respond to TGF-beta due to intact 
TGF-beta signaling and that the mutant cells are non-reponsive due to 
disruption/alteration of this pathway resulting from the absence of p53.  To test this 
hypothesis, I inhibited TGF-beta signaling in wildtype cells by SB431542 that inhibits 
TGF-beta signaling via inhibition of TGF-beta receptors. 2000 cells/well were taken in 
a 24 well plate and treated with 25nM of SB431542. SB431542 prevented the TGF-
beta induced growth arrest and the NSC continued to proliferate (Fig. 26A). The 
mutant cells, on the other hand, did not show significant response to the inhibitor 
SB431542. The growth pattern of mutant cells under all the conditions was almost 
similar (Fig. 26B).  
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Figure 26. Abrogation of the TGF-beta signaling pathway does not change 
growth pattern of p53-/- cells. (A, B) Representative images of wildtype and 
mutant cells with and without TGF-beta signaling inhibition. Scale bars, 500µm. 
 
SB431542 rather enhanced the proliferation of wildtype NSC, thus suggesting 
an anti-proliferative autocrine TGF-beta signaling loop under normal conditions. 
The increased proliferation rate was also reflected by an increase in sphere/patch 
size (Fig. 27A). There was a minor increase in sphere size in the mutant cells 
incubated with SB431542 that did not reach significance (Fig. 27B). 
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Figure 27. Increase in sphere size of wiltype cells upon TGF-beta signal blockade. 
(A, B) 100 cells per well were plated in a 96-well plate. The following day they were 
treated with 25nM of SB431542. Two hours later they were treated with 10ng/ml of 
TGF-beta1 and 2. After 4 days the sphere size was measured. There was an increase in 
sphere size of wildtype cells when the TGF-beta signaling was blocked after 
incubation with 25 nM of SB431542. In contrast, not much change was observed in 
case of mutant cells.  
  
7.5 Discussion 
The last 30 years since the discovery of p53, its role has mostly been involved 
with cellular response to stress in developing and homeostatic tissues. Recent studies 
have identified the role of p53 in self-renewal (Meletis et al., 2006). Also, p53 is 
expressed in the neurogenic niche in the lateral ventricle wall in adult mice brain 
(Meletis et al., 2006). P53 is present in substantial amounts in the NSC and progenitor 
cells compared to more differentiated cells in the adult brain (Meletis et al., 2006). The 
neurogenic niche shows increased proliferation in the absence of p53 (Meletis et al., 
2006). Loss of p53 has also been shown to facilitate the generation of iPS cells, which 
are now been argued to share similarities with the CSC (Lottaz et al., 2010). From my 
research, I found that the GBM CSC show a heterogeneous response to TGF-beta 
incubation. The molecular basis for this lack of responsiveness was the 
downregulation of TGFBR2. It has also been reported that mutant p53 protein 
abrogates the TGF-beta anti-proliferative control by downregulating TGFBR2 (Kalo et 
al., 2007). Thus the disruption of TGF-beta signaling seems to be important for a 
subset of GBM. Also, in most of the GBM p53 is deleted, mutated or inhibited. Lack 
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of activation mechanisms renders p53 non-functional in tumors where it is present in 
wild type form. Introduction of wild type p53 in tumors have resulted in decrease in 
tumor burden. In line with this, activation of p53 small molecules targeting p53-Mdm2 
interaction has also shown promising results. Thus overcoming p53 control is 
imperative for tumor formation and restoration of p53 function in tumors lacking it 
results in decreased tumor burden (Ventura et al., 2007). Based on these observations 
it was hypothesized that the loss of p53 could result in loss of response to anti-
proliferative effects of TGF-beta in SVZ NSC.  
There have been previous reports where the TGF-beta and p53 signaling 
pathway have been shown to converge. Studies in Xenopus revealed that Smads 
require p53 for effects which are similiar to effects produced by TGF-beta 
(Cordenonsi et al., 2003; Takebayashi-Suzuki et al., 2003). Although there is a large 
overlap in activity of TGF-beta and p53, it is not complete as p53 is unable to activate 
some TGF-beta targets like goosecoid, Xnr-1 and Wnt-8 (Cordenonsi et al., 2003; 
Takebayashi-Suzuki et al., 2003). Thus there is only a subset of TGF-beta target 
promoters which require p53 for activation. For an effective TGF-beta induced 
transcription p53 has to associate with Smad2 and Smad3 in a TGF-beta dependent 
manner and at the same time it also has to associate with its own cognate site on a 
promoter (Cordenonsi et al., 2003). Mix.2 and plasminogen activator inhibitor-1 (PAI-
1) promoters involved in TGF-beta transcription contain p53-binding element in close 
proximity to the TGF-beta enhancer. Mutations disrupting these p53 elements results 
in loss of inducibility of these reporters by TGF-beta. Also, overexpression of p53 
leads to an enhancement of TGF-beta induced transcription of the same reporters. 
Additionally point-mutations that disrupt the DNA binding ability of p53 block its 
ability to enter into a Smad-activated transcriptional complex (Cordenonsi et al., 
2003).  
In mammalian systems also, p53 and TGF-beta signaling interaction has been 
observed. Loss of p53 in hepatoma cell line HepG2 leads to a complete lack of TGF-
beta-induced expression of genes like MMP-2, PAI-1, and p21(Cordenonsi et al., 
2003). This could have important implications in the stem cell compartment too as it 
was observed that TGF-beta1 specifically arrested neural stem and progenitor cells in 
the G0/1 phase of the cell cycle (Wachs et al., 2006). 
Interestingly, HaCaT kerationocytes with inactivated p53 allele show cytostatic 
response to TGF-beta (Datto et al., 1995). Blocking p63 by siRNA transfection in 
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HaCaT kerationocytes  showed an attenuated induction of p21 by TGF-beta 
(Cordenonsi et al., 2003). This proved that although p53 may be the major modulator 
of TGF-beta induced cytostatic response, it is not the only one involved. P53 siblings, 
p63 and p73 could also be involved and in several epithelial cells p53 is a fraction of 
p63/p73. In other words, p63/p73 isoforms can take-over in the absence of 
p53(Levrero et al., 2000). 
Since there are no proper markers to precisely identify NSC in vivo, NSC 
behavior, including self-renewal and differentiation properties can be can be assessed 
using neurospheres (Reynolds and Weiss, 1992; Mendrysa et al., 2011). Neurospheres 
are floating aggregates of heterogeneous cell types and include neural stem and 
progenitor cells (Reynolds and Weiss, 1992; Mendrysa et al., 2011). I observed that 
the neurospheres established from the adult SVZ of p53 mutant mice have higher 
proliferation rate and enhanced capacity for self-renewal than their wildtype 
counterparts as reported earlier (Gil-Perotin et al., 2006; Meletis et al., 2006; 
Armesilla-Diaz et al., 2009; Stecca and Ruiz i Altaba, 2009).  Interestingly and in line 
with my hypothesis I also observed the non-responsiveness of the mutant cells to 
TGF-beta incubation. In contrast, the wildtype cells as reported earlier (Wachs et al., 
2006), showed proliferation arrest.   
There are multiple ways in which the TGF-beta signaling could be interrupted. 
As mentioned earlier, in a subgroup of GBM CSC this was the loss of TGFBR2. I 
found that all the NSC lines showed intact TGFBR2. This was confirmed by time 
dependent Smad2 phosphorylation in response to TGF-beta incubation in both 
wildtype and mutant lines. I then checked the presence of the other major components 
of the TGF-beta signaling pathway. The presence of Smad2 and Smad7 in all the cell 
lines showed that the canonical TGF-beta signaling pathway was intact in all the cell 
lines.  
Inhibition of TGF-beta signaling by the inhibitor SB431542 resulted in 
increase in proliferation of wildtype cells. It had no effect on the mutant cells. This 
confirmed that the anti-proliferation response in wildtype cells was TGF-beta specific 
and this pathway was not active in the mutant cell lines. 
There was no change in clonogenicity of either the wildtype or the mutant NSC 
after TGF-beta treatment. This was in line with my previous study with the GBM CSC 
where TGF-beta did not bring about any change in the stem cell characteristics of any 
of the cell lines, although there was profound heterogeneity in response. 
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Although confirmatory experiments in vivo have to be carried to prove the 
functional relevance of this interaction, these results suggest that p53 is needed for 
TGF-beta induced proliferation arrest in vitro. Conversely, the loss of TGF-mediated 
growth arrest contributes to the increased proliferation in the SVZ after loss of p53 
function.  
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8 General Discussion 
The cure for glioblastoma remains elusive even though the presence of CSC 
has been shown. Given that almost all classical chemotherapies failed to impove the 
patients’ survival, new therapeutic approaches are needed that should specifically 
target signaling pathway essential to the tumors. Targeting TGF-beta signaling is 
among the most promising approaches to treat GBM (Wick et al., 2006; Zhang et al., 
2011). The main idea behind this study was to clarify the role of TGF-beta in GBM 
CSC, to identify a biomarker for TGF-beta response and to identify the initial steps 
leading to the transformation of NSC to CSC.  
First I would discuss the response of GBM CSC to TGF-beta and then I would 
discuss the p53 dependent anti-proliferative response of TGF-beta in the NSC 
compartment. 
The GBM CSC lines showed heterogeneous responses to TGF-beta incubation 
with some cell lines being completely resistant and some responding strongly. In the 
responsive cell lines, the canonical TGF-beta signaling pathway components were 
intact while the resistant CSC lines lacked TGFBR2 expression suggesting that 
TGFBR2 downregulation was responsible for the resistance towards TGF-beta. This is 
in line with previous studies that have shown a correlation between decreased 
expression of TGFBR2 and high grade of tumors in human cancers (Kim et al., 2000b) 
and also in other experimental systems (Tang et al., 1999; Venkatasubbarao et al., 
2000; Kim et al., 2001; Lee et al., 2001).  
The lack of active TGF-beta production by the GBM CSC in vitro was also a 
novel finding. There have been numerous previous reports about the enhanced TGF-
beta production by the tumor cells but these studies involved conventional tumor cell 
lines which have been proved to be genetically and transcriptionally different from the 
parental tumors from which these cell lines were isolated. Also, the presence of active 
TGF-beta in the patient tumor samples opens up new avenues to be explored involving 
the interaction of these CSC with tumor microenvironment which may lead to the 
activation of TGF-beta in these tumors. Interestingly, when proneural Type I GBM 
CSC lines were cocultured with PBMC there was an increased TGF-beta dependent 
dowregulation of NKG2D receptor on CD8+ T-cells and CD56+ NK-cells. This effect 
was lacking when only the supernatants of the cell lines were cocultured with PBMC 
(Beier et al., 2012). This phenomenon was reversed in the presence of SD-208 which 
is a TGFBR1 kinase inhibitor. This immune suppressive role of TGF-beta was further 
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validated when patient tumor samples of Type I and Type II GBM were stained for 
CD8+ (T-lymphocytes) and CD68+ (microglia). The level of immune infiltration 
varied between the types of tumor. In case of mesenchymal Type II tumor samples 
there was enhanced presence of CD8+ and CD68+ cells. Thus, the proneural Type I 
CSC not only negates the antiproliferative effect of TGF-beta by downregulating 
TGFBR2 but also subdues the infiltration of T-lymphocytes and microglia. 
In a parallel project, I worked on the TGF-beta-p53 axis in the NSC isolated 
from SVZ of mice. There is ubiquitous p53 mRNA expression in the rodent brain 
during early embryogenesis up to embryonic day 10.5 (Rogel et al., 1985; Schmid et 
al., 1991). P53 expression becomes more heterogeneous during mid-gestation which is 
marked with enhanced cell specification and differentiation leading to organogenesis. 
P53, although being known for almost 30 years and being involved in almost all the 
major cell responses has only recently been implicated to play a role in the self-
renewal of stem cells. Recent data have also indicated the existence of cells with stem 
cell like potential in tumors. Thus there is an enhanced interest in the role of p53 in the 
stem cell compartment. Also, p53 has been reported to be expressed by the cells of 
neurogenic niche of lateral ventricles in adult mice brain (Meletis et al., 2006). In 
majority of GBM there is either deletion or mutation of p53 and my results showed 
that a subset of GBM was resistant to TGF-beta. Also, in the initial stages of 
tumorigenesis TGF-beta has anti-proliferative role. There have been previous reports 
on the convergence of p53 and TGF-beta signaling. This led me to explore if this 
convergence also exists in the neural stem cell compartment and if the loss of this axis 
may have implications in the origin of tumors. The lack of response to TGF-beta by 
the mutant (p53-/-) cells do point to the role p53 plays in transduction of TGF-beta 
signal in the NSC. Also, the presence of major components of TGF-beta signaling 
showed that the TGF-beta signaling is p53 specific in NSC. 
This study shows that TGF-beta is involved in immune-paralysis in a subset of 
GBM which could be identified by the 24-gene signature. The downregualtion of 
tumor infiltrating lymphocytes in case of proneural CSC clarifies the reason for the 
failure of certain vaccination therapies. Also, TGF-beta converges on p53 for its anti-
proliferative control of the NSC. 
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9 Summary 
The function of TGF-beta in glioblastoma cancer stem cells (GBM CSC) was 
unknown at the beginning of this thesis. In a series of 9 different CSC lines, I observed 
varying response of the cell lines to TGF-beta incubation. Most of the cell lines were 
completely resistant, 2 cell lines showed growth inhibition and surprisingly in one of 
the cell lines there was growth promotion. A detailed characterization of the effects of 
TGF-beta showed that TGF-beta did not modulate bona fide stem cell properties but 
rather proliferation and migration in vitro. In vivo TGF-beta significantly modulated 
the tumor size of TGF-beta treated and orthotopcially implanted CSC. However, the 
responsiveness to TGF-beta was not random. Earlier reports of my group suggested 
that different types of CSC lead to the formation of GBM. These two groups show 
distinct transcriptional profiles and display substantial differences with respect to 
TGF-beta related transcripts. The experiments in this thesis now prove that the 
assignment to a specific CSC type was associated with the role of TGF-beta in the 
respective CSC lines in vitro and in derived GBM in vivo. In summary, TGF-beta acts 
either as paracrine immunosuppressor in CD133+ proneural-like CSC and GBM or as 
tumorpromoter/-suppressor in CD133- mesenchymal-like CSC and GBM. This 
heterogeneity in response to TGF-beta has substantial implication for various anti-
TGF-beta therapies presently underway as it could be counter-productive in GBM in 
which it acts as tumor suppressor. In addition, the reduced immune-paralysis in 
mesenchymal GBM makes them optimal targets for immunotherapies.  
In the second part I focused on the role of TGF-beta in the NSC from SVZ of 
mice lacking p53 and compared the results with similar NSC from mice that had p53. 
In line with the published results it was observed that the p53-/- cells proliferated faster 
than p53+/+ cells. Importantly, the p53+/+ but not p53-/- cells showed proliferation arrest 
in response to TGF-beta treatment. This lack of response was observed even though 
the major components of TGF-beta signaling were intact. Conversely, the blocking 
TGF-beta signaling in p53+/+ cells showed enhanced proliferation whereas there was 
no change in case of p53-/- cells suggesting that the loss of inhibitory autocrine TGF-
beta signaling on NSC contribute to the proliferation of NSC after loss of p53 activity. 
Given that mounting evidence suggest the origin of GBM CSC from NSC, this study 
provides cues to the initial steps in the origin of GBM from NSC.  
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Taken together, alteration of TGF-beta signaling is an early event in the 
genesis of GBM and remain of relevance in GBM although with variable biological 
function.  
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10 Zusammenfassung 
 
Die Funktion von TFG-beta in Tumorstammzellen (TSZ) des Glioblastoms war 
zu Beginn der Doktorarbeit vollkommen unklar. Die Untersuchung einer Serie von 9 
verschiedenen TSZ Linien ergab unterschiedliche Effekte. Die meisten Zelllinien 
waren vollständig resistent gegenüber den Effekten von TGF-beta, in 2 TSZ Linien 
kam es zu einer Wachstumsverlangsamung, eine TSZ Linie wuchs dagegen besser. 
Eine genaue Analyse der TGF-beta Effekte zeigte, dass TGF-beta nicht die 
eigentlichen Tumorstammzelleigenschaften, sondern nur Proliferation und Migration 
in vitro beeinflusste. In vivo beeinflusste TGF-beta die Größe der gebildeten Tumoren 
nach orthotoper Implantation von behandelten TSZ. Die Effekte von TGF-beta auf 
TSZ waren allerdings nicht zufällig: Frühere Arbeiten der Arbeitsgruppe konnten 
bereits zeigen, dass mindestens zwei unterschiedliche Typen von TSZ zur Bildung von 
GBM führen können. Die beiden Gruppen haben spezifische transkriptionelle Profile 
und zeigen substantielle Unterschiede bezüglich der Expression von TGF-beta 
assoziierten Transkripten. Die Experimente in dieser Doktorarbeit zeigen nun, dass die 
Zuordnung zu einem TSZ Typ mit der Funktion von TGF-beta sowohl in vitro als 
auch in vivo assoziiert ist. Zusammenfasend wirkt TGF-beta in CD133+ proneuralen 
TSZ und GBM lokal immunsuppressiv während es in CD133- mesenchymalen TSZ 
und GBM als Tumorpromotor oder –suppressor wirkt. Diese Heterogenität der 
Wirkung von TGF-beta hat erhebliche Auswirkungen auf die verschiedenen gegen 
TGF-beta gerichteten Therapieansätze, die aktuell in der klinischen Erprobung sind. 
Dies gilt insbesondere für Tumoren, in denen TGF-beta tumorsuppressiv wirkt.  
Weiterhin sind mesenchymale GBM auf Grund der geringeren Immunsuppression ein 
optimales Ziel für Immuntherapien.   
Im zweiten Abschnitt der Arbeit wurde die Rolle von TGF-beta in neuralen 
Stammzellen (NSC) aus p53 defizienten Mäusen im Vergleich zu Kontrolltieren 
untersucht. Wie aus publizierten Vorarbeiten bekannt war, proliferierten p53-/- Zellen 
schneller als p53+/+ Zellen. Auffällig war, das nur die p53+/+ nicht aber die p53-/- 
Zellen einen Wachstumsarrest auf TGF-beta Behandlung zeigten. Dieser Verlust des 
TGF-beta Ansprechens war trotz des Vorhandenseins aller relevanten Komponenten 
des TGF-beta Signalwegs nachweisbar und ist auf das direkte Fehlen von p53 als 
Kofaktor für den SMAD2/4 Komplex zu erklären. Umgekehrt führt die Blockierung 
des TGF-beta Signalwegs nur in p53+/+ NSC nicht aber in p53-/- NSC zu einer 
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erhöhten Proliferation, was einen autokrinen, negativen Rückkoppelungsmechanismus 
nahe legt, der zu der erhöhten Proliferationsfrequenz von p53-/- NSC beiträgt. Unter 
Berücksichtigung der Hinweise auf eine Entstehung von GBM aus NSC, liefern diese 
Ergebnisse mögliche Ansatzpunkte für den Ablauf der frühen Schritte in der 
Tumorigense von GBM aus NSC. Zusammenfassend zeigt die Arbeit, dass 
Veränderungen des TGF-beta Signalwegs ein früher Schritt in der Entstehung von 
GBM sind, die auch im Tumor von - wenngleich unterschiedlicher - Relevanz bleiben. 
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